Document:

EX-4.13

 Exhibit 4.13 

RESEARCH FUNDING AND SUPPLY AGREEMENT 
 This
Agreement (the “Agreement”), effective as of _June 11, 2019 (“the Effective Date”), by and between Alliance for Clinical Trials in Oncology Foundation, an Illinois
not-for-profit corporation, with its principal office at 125 S. Wacker Drive, Chicago, IL 60606 (“Foundation”) and Kazia Therapeutics Limited (ABN 37 063 259
754), a publicly-listed company with its principal office at L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Kazia”). Kazia and Foundation may be referred to as “Party” individually, and collectively as the
“Parties”. 
 RECITALS 

WHEREAS, Foundation is an Illinois not-for-profit
corporation that was formed to facilitate and support the Alliance for Clinical Trials in Oncology (“Alliance”), a member of NCI’s National Clinical Trials Network (“NCTN”) and a research base for the NCI Community Research
Oncology Program (“NCORP”); 
 WHEREAS, The Alliance is comprised of academic and community institutions, statistics, data,
and operations centers and their affiliates which conduct cancer treatment and cancer control/prevention studies and related research according to their policies and procedures and in accordance with all applicable federal, state and local laws and
regulations including, without limitation, FDA regulations and guidelines for good clinical practice; 
 WHEREAS, Foundation shall
facilitate and support the Study at each Participating Site by performing, in accordance with the provisions of this Agreement, the activities described in the SOW (“Scope of Work”) attached hereto as Exhibit A and incorporated into the
Agreement by this reference; 
 WHEREAS, Kazia is a public company listed on the Australian Securities Exchange (ASX) and on NASDAQ,
whose primary business is the discovery, development, and commercialization of new therapies for cancer; 
 WHEREAS, Kazia seeks to
develop GDC-0084, a small molecule, orally available, selective inhibitor of the PI3K/Akt/mTOR pathway, for several forms of primary and secondary brain cancer. 

WHEREAS, the Alliance, through the Foundation, wishes to undertake a clinical trial entitled: “A071701 GENOMICALLY-GUIDED TRIAL
IN BRAIN METASTASES”, (“the Study”). Foundation and Kazia now wish to collaborate on the Study and Kazia has agreed to provide support through funding and through supplies of the Study Drug for the Study and to provide such
information, advice, and assistance as may be required during the course of the Study and pursuant to the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the foregoing and mutual covenants and promises set forth herein and other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	 DEFINITIONS 

For purposes of this Agreement: 
  

	1.1	 “Affiliate” means, with respect to a Party, any corporation or other business entity controlled by,
controlling or under common control with that party. “Control” for the purposes of this definition shall mean direct or indirect beneficial ownership of fifty percent (50%) or more of the voting interest in an entity, or such other
relationship as, in fact, constitutes actual control. 

	1.2	 “Applicable Law” means all applicable local, state, and federal laws, rules and regulations and other
governmental requirements relating to the performance of their respective responsibilities under this Agreement, that may be in effect from time to time, including, but not limited to, the Federal Food, Drug and Cosmetic Act of 1938, as amended (the
“Act”), and all applicable regulations promulgated thereunder including regulations of the United States Food and Drug Administration or its foreign equivalent, including, without limitation, 21 C.F.R. Parts 50, 54, 56, and 312 (the
regulations governing the protection of human subjects, financial disclosure of clinical investigators, Institutional Review Boards or its foreign equivalent, and investigational new drug applications), and including without limitation all
applicable good practice quality guidelines and regulations encompassing internationally recognized standards (as adopted by the FDA and as related to guidance provided by NCI, NCORP, CTMB and OFIRP guidelines) such as Good Manufacturing Practice,
Good Clinical Practice (as adopted by the FDA), Good Laboratory Practice, Good Distribution Practice and Good Review Practice (collectively, “GxPs”), FDA Form 1572 Statement of Investigator, the federal Anti-Kickback Statute (42
U.S.C. § 1320a-7b), and state and federal False Claims Acts, as well as all applicable data protection and medical privacy laws or regulations, including, the Health Insurance Portability and
Accountability Act of 1996 (HIPAA), as amended by Subtitle D of the Health Information Technology for Economic and Clinical Health Act (“HITECH”) and the Standards for Privacy of Individually Identifiable Health Information 45 C.F.R. Parts
160 and 164. 

  

	1.3	 “Background IP” of a Party means information, techniques,
know-how, software and materials (regardless of the form or medium in which they are disclosed or stored) that are provided by or on behalf of that Party to the other for use in the Study (whether before or
after the date of this Agreement), and all improvements and Intellectual Property in them prior to or on the Effective Date of this Agreement, but excludes the Study Data. For the avoidance of doubt, the Study Drug and all improvements and
Intellectual Property in the Study Drug separate from any Intellectual Property developed under this Agreement and through the conduct of this Study, will be Kazia’s Background IP. Any Intellectual Property developed under this Agreement and
through the conduct of the Study will be handled in accordance with Section 10 and Annex B. 

  

	1.4	 “Budget” means the budget set out in Annex A, as amended by the Parties from time to time.

  

	1.5	 “Biospecimens” means blood serum, urine, stool, saliva, other bodily fluid, bone marrow, cells, or
tissue samples/specimen collected from Subjects. The term “Biospecimen” further includes, without limitation, any tangible material directly or indirectly derived from such Biospecimens collected under the Protocol from Subjects, such as
genes, gene fragments, gene sequences, proteins, protein fragments, protein sequences, DNA, RNA, and any subcellular structure. 

  

	1.6	 “Intellectual Property” means all present and future industrial and intellectual property rights,
including without limitation: (i) inventions, patents, copyright, trade business, company or domain names, rights in relation to, registered designs, registered and unregistered trade marks, know how, trade secrets and the right to have
confidential information kept confidential, and any and all other rights to intellectual property which may subsist anywhere in the world; and (ii) any application for or right to apply for registration of any of those rights.

  

	1.7	 “Investigator Brochure” is a compilation of the clinical and
non-clinical data on the Study Drug which is relevant to the study of the Study Drug in humans. 

  

	1.8	 “NCI” means the National Cancer Institute, a division of the National Institutes of Health, an agency
of the U.S. Department of Health and Human Services; 

  

	1.9	 “Protocol” means the final protocol document, for the Study entitled “A071701 Genomically-guided
trial in brain metastases”. The entire Protocol is incorporated into this Agreement by reference and is made a part of this Agreement as though fully set forth herein. In the event of any conflict or inconsistency between the terms and
provisions of this Agreement and those of the Protocol, the terms and provisions of this Agreement shall control. 

  

	1.10	 “Participating Investigator” shall mean an investigator who conducts the Study at a Participating
Site, as defined below. “Alliance Participating Investigator” shall mean a Participating Investigator conducting the Study at an Alliance Participating Site, as defined below. 

	1.11	 “Participating Site” means any hospital or similar institution, based or located in the United
States, that is a member of an NCTN Cooperative Group and participating in the Study. “Alliance Participating Site” shall mean a Participating Site that is an Alliance member institution. 

 

	1.12	 “Publishable Manuscript” means a final report summarizing the findings of the Study that is in a form
suitable for submission to a peer-reviewed journal. 

  

	1.13	 “Sponsor,” as that tennis defined in 21 C.F.R. § 312.3(b), refers to Alliance, through the
Foundation, which is the party that is taking responsibility for, initiating and conducting the Study in accordance with the Protocol. Under no circumstances will Kazia be deemed the Sponsor of the Study. 

 

	1.14	 “Study” means the work performed in connection with the Protocol. 

 

	1.15	 “Study Data” means as defined in Section 5 of this Agreement. 

 

	1.16	 “Study Results” means as defined in Section 5 of this Agreement. 

 

	1.17	 “Study Drug” refers to GDC-0084, 15mg capsules, for oral
administration, which will be supplied in labeled bottles. The bottle label text has been agreed between the parties, and includes the statement “Limited by Federal (US) Law to Investigational Use”. Study Drug responsibilities detailed
further in Annex C. 

  

	1.18	 “Study Staff’ means all employees, agents and/or authorized representatives of the Foundation or any
Participating Site, engaged in the Study and includes, the Participating Investigator. 

  

	1.19	 “Subject,” as that term is defined in 21 C.F.R. § 312.3(b), means a human being who participates
in the Study. 

  

	2.	 STUDY CONDUCT 

The Parties understand and agree that Foundation shall facilitate and support the Study in accordance with the following: 

 

	 	2.1.	 The terms of this Agreement and all Applicable Laws 

 

	 	2.2.	 the Protocol, as approved by NCI and the responsible Institutional Review Board (“IRB”). All
substantial changes to the Protocol shall be submitted to NCI for written approval before implementation, excluding those immediately necessary to protect the safety, rights, or well being of the Subjects. All such amendments will be incorporated
herein by reference. Foundation, on behalf of the Alliance, shall notify Kazia of any significant amendment made to the Protocol prior or during the conduct of the Study. A significant amendment to the Protocol shall be defined as any modification
to the Protocol which may impact the overall conduct of the Study, the scientific value of the Study, the potential benefit of the patient or patient safety, including changes of Study objectives, patient population, and samples sizes.

  

	 	2.3.	 Before beginning the Study, Foundation, through the Alliance, shall have either an effective Investigational
New Drug Application (“IND”) on file with the U.S. Food and Drug Administration (“FDA”), or a determination by the Alliance and NCI that the Study is exempt (within the meaning of 21 C.F.R. Sec. 312.2(b)) from the IND
requirements of 21 C.F.R. Part 312. Kazia will provide a letter of cross reference to the FDA to its US IND, with a copy to Alliance for Alliance to include in its IND filing. 

 

	 	2.4.	 Enrollment for the Study will begin when all NCTN requirements have been met and NCI and the responsible IRB
have provided final approval for the Study. The Budget will provide enrollment payment milestones and invoicing instructions. Neither Foundation nor Participating Sites shall enroll a number of subjects into the Study that exceeds the then-current
target number set by the Protocol without the prior written agreement of NCI. Foundation will communicate to all Participating Sites, through the Protocol, the predetermined enrollment period after initiation of the Study, unless otherwise agreed by
the Parties. 

  
 3 

 Foundation will ensure that all Participating Sites and Investigators do not enroll any
subjects (i) except as permitted by the Protocol; and (ii) following expiration of the enrollment period without written authorization from NCI. 
  

	 	2.5.	 Foundation, as well as each of the Participating Sites and any vendors or subcontractors used by Foundation to
carry out any aspect of the Study, are expected to adhere to the NCTN guidelines, the Alliance Policies and Procedures, and the Protocol. Foundation shall use reasonable efforts to ensure that, Participating Sites, vendor and subcontractors are
aware of their obligations regarding NCTN guidelines, the Alliance Policies and Procedures, and the Protocol and comply with NCTN guidelines, the Alliances Policies and Procedures, and the Protocol. 

 

	 	2.6.	 Foundation, on behalf of Alliance, shall ensure that the Study and post Study Results are registered on
ClinicalTrials.gov and/or any other Internet clinical trial registries in accordance and compliance with all Applicable Laws. Foundation shall ensure that each posting complies with all applicable requirements of this Agreement.

  

	 	2.7.	 The Study is to be completed and the Foundation must ensure that a final draft of a primary end point
publication summarizing the findings of the Study (“Publishable Manuscript”), as further detailed in Section 9, is to be submitted to Kazia within 12 months of completion of the Study, assuming that the Data and Safety Monitoring
Board (“DSMB”) has permitted data to be released in this time period, following completion of the Study (that is enrollment of all Study subjects and completion of Protocol requirements for the Study at all Participating Sites, and the
achievement of adequate events for the analysis of the primary objective of the Study, in accordance with the Protocol), unless (i) a shorter period is mutually agreed between the Parties. The Publishable Manuscript shall summarize the results
and interpretation of the Study, including, but not limited to the Study design, Study objectives, patient assessment, data analysis, results, safety and effectiveness. 

 

	 	2.8.	 If the Study terminates early the Foundation, through the Alliance, may proceed to publish study results,
dependent on the circumstances of the early termination with approval from the DSMB and NCI, and report study results to clinicaltrials.gov with in required regulatory timeframe. The Alliance may all prepare a final study summary to be published by
the next Alliance Group Meeting. 

  

	3.	 KAZIA OBLIGATIONS 

 

	 	3.1.	 Kazia represents and certifies to Foundation that (i) it possesses the full legal right and authority to
enter into this Agreement and enters this agreement willingly; (ii) to the best of its knowledge and information, it has no obligations to any third party which would conflict with its obligations hereunder; and (iii) the Study Drug has
been manufactured, stored, shipped and delivered in accordance with all applicable laws, rules, and regulations. Kazia further represents that all Study Ding delivered under the Agreement complies at the time of delivery with the specifications for
the Study Ding (which specifications shall be communicated to Foundation by Kazia prior to shipment of any Study Drug to Alliance or its designee). 

  

	 	3.2.	 Kazia agrees to provide Foundation with an updated Investigator’s Brochure, any appropriate cross-
referencing letters, and with appropriate and timely safety information related to the Study Drug. 

  

	 	3.3.	 Kazia shall supply Foundation with funding for and with sufficient supplies of, the Study Drug to support the
Study in accordance with the Budget and the Protocol and any amendments thereof. 

  
 4 

	4.	 FUNDING AND PAYMENT SCHEDULE 

 

	 	4.1.	 Kazia has agreed to provide financial support for the Study and this funding will be provided to Foundation
according to the Budget set out in the Funding and Payment Schedule (Exhibit A) attached hereto. The Parties agree that the amounts set forth in Exhibit A are based on the fair market value of the activities performed and provide an accurate
breakdown of the cohort Study costs and expenses. Any funding provided under this Agreement is provided as an independent grant and is not conditioned in any way on any pre-existing or future business
relationship between or among Foundation and Kazia. No amounts paid under this Agreement are intended to be for, nor shall they be construed as, an offer or payment made in exchange for any explicit or implicit agreement to purchase, prescribe,
recommend, or provide a favorable formulary status for any Kazia product or service. 

  

	 	4.2.	 Each milestone payment is contingent upon the receipt of an invoice, which will include detail regarding the
milestone achieved, acceptable to Kazia, signifying the achievement of the related milestone. Foundation shall submit an invoice to Kazia once each milestone is achieved and becomes payable, and Kazia shall pay the applicable amount within thirty
(30) days after its receipt of such invoice which will include detail regarding the milestone achieved. Foundation agrees to use the compensation provided under this Agreement solely for the purposes of facilitating and supporting the Study.
All payments which are otherwise due and owing under this Agreement shall be paid by Kazia to, and only to, the Foundation. Foundation agrees to arrange payments due to Participating Sites for the performance of the Study hereunder. Kazia shall not
be responsible for making payments directly to Participating Sites for any such Study costs and expenses. Any taxes (and any penalties thereon) imposed on any payment made by Kazia to Foundation shall be the responsibility of Foundation.

  

	 	4.3.	 ACH payments to be made to Foundation hereunder will be made payable to: 

Alliance For Clinical Trials in Oncology Foundation 

125 S. Wacker Drive, Suite 1600 Chicago, IL 60606 

Federal Tax ID# 02-0464400 Attn: Sylvia Hrbek 

 

	 	4.4.	 Kazia shall not be obligated to make any payments to Foundation in excess of the amount provided for under
Exhibit A, unless such excess amount is agreed upon in writing and signed by the Parties. 

  

	 	4.5.	 Foundation must promptly repay to Kazia: (a) subject to Section 12, any funds paid by Kazia to
Foundation which are unspent from the study at termination of this Agreement; and (b) any funds paid by Kazia to Foundation which have been used for a purpose other than in accordance with this Agreement and the Budget. 

 

	5.	 STUDY DATA, STUDY RESULTS AND BIOSPECIMENT RESEARCH 

For purposes of this Agreement, “Study Data” means the raw, non-aggregated data collected about each Study
subject, including Biospecimen data, during the course of the Study. “Study Results” refers to aggregated or summarized Study Data and conclusions about the Study, as would be included in a study report or publication. All Study Data and
Study Results generated from this Study are the property of Foundation, through the Alliance. 
 The Study Results related to the Study Drug will be
provided to Kazia on completion or termination of the study, in a form no less detailed than would be required for Alliance to fulfil its obligation to publish the study as described in clause 2.7. Upon reasonable request by Kazia, Study Data
related to the Study Drug may also be provided to Kazia by Alliance, at Kazia’s cost as detailed in an amendment to this agreement or separate data transfer agreement, which is subject to approval by Alliance leadership and the NCI, such
approval not to be unreasonably withheld, and DSMB release of Study Data and Study Results. 
 Kazia shall be free to use Study data and results for all
lawful purposes, including any submission to a health authority. 

  
 5 

 Both Parties agree to comply with any and all laws relating to patient privacy which are applicable to such
Party. Foundation, through the Alliance, will ensure all Study Data and Study Results are de-identified as appropriate prior to transferring such data to Kazia. 

 

	6.	 SAFETY REPORTING 

 

	 	6.1.	 Foundation, through the Alliance, shall comply with all applicable safety reporting requirements involving the
Study Drug, including the requirements set forth in 21 C.F.R. § 312.32. 

  

	 	6.1.1.	 All suspected not unexpected serious adverse events are hereinafter “SAEs”. All suspected and
unexpected serious adverse events are hereinafter “SUSARs”. 

  

	 	6.1.2.	 Foundation shall be responsible for ensuring that adverse events and other relevant safety information are
recorded as specified in the Protocol and appropriately reported to the relevant health authorities, ethics committees and Study investigators according to Applicable Laws. Foundation shall forward such safety information to Kazia at the same time
it is provided to relevant govemment/regulatory authorities. 

  

	 	6.1.3.	 Foundation shall ensure that any SUSARs, including initial and follow up reports, arising from the Study in
Subjects exposed to the Study Drug, are forwarded within the applicable reporting timelines to the FDA, with a copy being sent to the Kazia at the same time and shall ensure that all non- SUSAR SAEs are
forwarded to the Kazia on an approximately monthly basis. Foundation shall also provide Kazia with a copy of the 1ND Annual Safety Update submission to the FDA at the same time it is provided to the FDA. 

 

	 	6.1.3.1.	 For each SUSAR report, arising from Subjects exposed to the Study Drug (both initial and follow-up reports), Foundation shall ensure that a CTEP AERS form completed with full information (as known at the time of forwarding) is forwarded to Kazia. 

 

	 	6.2.	 Foundation, through the Alliance, shall provide Kazia with an accrual and adverse event summary report every
six (6) months which will include aggregated toxicity/safety data, in a form mutually acceptable and agreed upon by the Parties, so that Kazia may fulfil its surveillance and reporting obligations to regulatory agencies. 

 

	 	6.3.	 Both Parties acknowledge that the Foundation/Alliance, as a grantee of the NCI, uses NCI’s electronic
reporting system, the Cancer Therapy Evaluation Program Adverse Event Reporting System (CTEP AERS), for SAE reporting. 

  

	 	6.4.	 Kazia will immediately notify Alliance of any changes to its contact information for reporting adverse events,
in order for Alliance to fulfill its notification obligations. 

  

	7.	 AGENCY INVESTIGATIONS 

 

	 	7.1.	 Foundation represents that it has no knowledge of any pending for cause regulatory audit, investigation or
proceeding involving Foundation or any Participating Investigator or Study Staff relating to compliance with laws regarding the conduct of any clinical research, and that neither Foundation nor any Participating Investigator or Study Staff has been
debarred under 21 U.S.C. § 335a, nor disqualified under 21 C.F.R. § 312.70 or § 812.119. In the event that Foundation or any Participating Investigator or Study Staff receives notice of initiation of any debarment or disqualification
proceeding by the FDA or notice of debarment or disqualification under the above-referenced statutes and Foundation learns of such notice, Foundation shall immediately notify Kazia in writing. 

  
 6 

	 	7.2.	 Unless otherwise prohibited from doing so by the FDA or other government agency, Foundation shall promptly
notify NCI and Kazia in writing in the event Foundation receives, or becomes aware that a Participating Site has received, either (1) notice from the FDA or other government agency that such agency plans to conduct an investigation at
Foundation, Alliance, or such Participating Site covering, in whole or in part, data or other activities relating to any study, or (2) an inquiry from the FDA or other government agency regarding, in whole or in part, data or other activities
relating to any study. So that Kazia may assist Alliance with its Participating Sites’ investigation readiness, Foundation will endeavor to provide such notice within one (1) business day if possible, but in any event within three
(3) business days. 

  

	 	7.3.	 Outside of the limited contacts that may be required to respond to a Participating Site’s investigation
readiness for an audit by the FDA or other government agency, or as otherwise required by law, Kazia will not reach out to Participating Sites directly in connection with the Study, nor will Kazia participate in any Participating Site visits in
connection with the Study. Communications with Participating Sites in the Alliance regarding the Study will be sent through Foundation to NCI and Kazia, as applicable or necessary. 

 

	8.	 CONFIDENTIALITY 

 

	 	8.1.	 Kazia Confidential Information and all tangible expressions, in any medium, of Kazia Confidential Information
are the sole and exclusive property of Kazia. Foundation Confidential Information and all tangible expressions, in any medium, of Foundation Confidential Information are the sole and exclusive property of Foundation. 

 

	 	8.2.	 Any confidential proprietary materials, data and/or information relating to business and/or technology of a
Party (“Confidential Information”) disclosed by one Party (“Disclosing Party”) to the other Party (“Receiving Party”) shall be retained by the Receiving Party in confidence and shall not be disclosed to any “Third
Party,” meaning an individual or entity other than an officer, director, employee or Affiliate of the Receiving Party, except as otherwise explicitly authorized in this Agreement or necessary to carry out the activities and obligations under
this Agreement, for a period beginning on the date of disclosure and ending ten (10) years after the expiration or early termination of the applicable Study. Confidential Information shall be designated or identified in writing as confidential
at the time of disclosure; provided however, if the nature of the Confidential Information being provided is such that a reasonable person familiar with the Study would understand that the Confidential Information should be treated as confidential
from the context and circumstances of disclosure, the disclosure shall still be protected as Confidential Information under this Agreement even if such Confidential Information is not expressly designated or identified as confidential.

  

	 	8.3.	 All Confidential Information of a Disclosing Party shall remain the property of the Disclosing Party. Except as
set out in this Agreement, no license or other intellectual property right to any Confidential Information of the Disclosing Party is created or granted to the receiving party by this Agreement, and disclosure of Confidential Information shall not
create any obligation to grant the Receiving Party any right in and to said information. 

  

	 	8.4.	 Upon the written request of the Disclosing Party, the Receiving Party shall immediately, in accordance with the
instructions of the Disclosing Party and subject to Applicable Laws, either return or destroy all Confidential Information of the Disclosing Party, including all notes, summaries, and translations that have been made regarding such Information, and
all copies of the foregoing, provided that: (i) the Receiving Party’s legal counsel may retain one (1) copy of the Disclosing Party’s Information in a secure location solely for purposes of identifying the Receiving Party’s
obligations hereunder; (ii) any Confidential Information contained in any board notes may be retained; and (iii) Receiving Party, and its Affiliates and/or designees required to meet the obligations under this Agreement, may retain a copy
of the Confidential information for internal and regulatory reporting puiposes. In the event destruction is requested by the Disclosing Party, the Receiving Party shall certify such destruction in writing. 

  
 7 

	 	8.5.	 Foundation and the Alliance shall not use Kazia Confidential Information for its own benefit or for any puipose
other than to conduct the Study. Foundation and the Alliance shall not disclose Kazia Confidential Information to Third Parties, other than NCI, except as necessary to conduct the Study and under an agreement by the Third Party to be bound by the
obligations of this Section 8. Foundation will be responsible for any unauthorized disclosures of Kazia Confidential Information by a Third-Party, to which Foundation has provided Kazia Confidential Information under an agreement. Foundation
shall maintain Kazia Confidential Information in strict trust and confidence and safeguard such information with the same standard of care that is used with Foundation’s own confidential information, but in no event less than reasonable care.

  

	 	8.6.	 The obligations of confidentiality and limited use under this Section 8 shall not extend to any
information: 

  

	 	8.6.1.	 which is or becomes publicly available, except through breach of this Agreement; 

 

	 	8.6.2.	 which the Receiving Party can demonstrate by competent written proof that it possessed prior to, or developed
independently from, disclosure by or on behalf of Disclosing Party or development under this Agreement; or 

  

	 	8.6.3.	 which the Receiving Party receives from a third party which is not legally prohibited from disclosing such
information. 

  

	 	8.7.	 If the Receiving Party is required by Applicable Law to disclose the other Party’s Confidential
Information, that Receiving Party (as applicable) shall give reasonable advance notice of such disclosure and use reasonable efforts to limit such disclosure and maintain the confidentiality of such Confidential Information to the extent possible.
In addition, the Parties shall cooperate if the Party whose Confidential Information is to be disclosed seeks a protective order or other confidential treatment for such Confidential Information by appropriate legal means. 

 

	 	8.8.	 For the avoidance of doubt, nothing in this Section 8 will limit a Party’s ability to publish and use
the published manuscript detailed in Section 9. 

  

	9.	 PUBLICATION 

 

	 	9.1.	 Foundation, through the Alliance, will reasonably ensure that the publication of Study results
(“Publishable Manuscript”) by Alliance shall be in accordance with Alliance’s Policies and Procedures. Foundation will ensure that Alliance provides a copy of the draft publishable manuscript to Kazia for review at least thirty
(30) days prior to submission for publication. In the case of presentations or abstracts, the Foundation shall ensure Kazia receives a copy of the draft presentation or abstract as early as possible prior to the disclosure, but in no event will
it be less than fifteen (15) days prior to submission for presentation. In the event that Kazia desires to seek patent or other intellectual property protection on information related to the Study Drug contained in the publication, Foundation
may agree to delay submission of the publication for up to an additional forty-five (45) days upon written request or notice by Kazia, as necessary to preserve U.S. or foreign patent or other intellectual property rights. 

 

	 	9.2.	 In accordance with National Cancer Institute (“NCI”) policy, Alliance maintains the full right to
present and publish the Study data and results at such time and place as it sees fit; provided, however, Kazia shall have the right to require deletion of its Confidential Information, provided that: (i) the Foundation will limit use of
Confidential Information to the extent reasonably practicable, and (ii) in no event will removal of Confidential Information by Kazia compromise the objective medical or scientific integrity of the disclosure, presentation or publication of the
Study results. 

  

	 	9.3.	 Once published Kazia will be able to copy and refer back to the provided manuscript/publication as needed for
their business or regulatory purposes. 

  
 8 

	 	9.4	 Publication includes presenting and publishing the Study data and results at symposia, national or regional
professional meetings, in professional journals, or through other means. Foundation shall not be required to obtain Kazia’s permission to repeat any information that was previously publicly disclosed by Alliance in accordance with this Section.

  

	10.	 INTELLECTUAL PROPERTY AND INVENTIONS 

 

	 	10.1.	 This Agreement does not affect the ownership of any Background IP. All Background IP shall remain the property
of the Party or its Affiliate that provided it to the other Party for use in the Study. 

  

	 	10.2.	 As between the Parties, any invention, discovery, or idea, whether patentable or not, other than the Background
IP, (an “Invention”) made during the conduct of the Study generally is the property of the Investigator or Participating Institution with which he or she is affiliated. 

 

	 	10.3.	 Foundation shall, no later than fifteen (15) business days upon becoming aware, notify Kazia of any
discovery or Invention (i) generated from the use of its Study Drug; or (ii) conceived or first reduced into practice or writing related to the Study Drug in the course of the Study or the performance of obligations under this Agreement.

  

	 	10.4.	 The NCI’s “Cancer Therapy Evaluation Program Intellectual Property Option to Co-Collaborators” terms of award shall apply to any Inventions made in the course of the Study, a copy of which has been attached as Annexure B. Kazia acknowledges that the Foundation, Alliance, Participating
Sites, and Investigators are bound by these intellectual property obligations. For purposes of this Study, Kazia shall be considered a “Collaborator” within the meaning of the Option. The Parties agree that any Inventions made during the
Study by Alliance and/or Other Investigators and/or Participating Sites will be subject to certain rights by Kazia and the other participating Collaborators as detailed in the Option. The Parties further agree that any and all updates to the Option
effective during the term of this Agreement shall be applicable to any such Inventions made during the Study. 

  

	11.	 TERM AND TERMINATION 

 

	 	11.1.	 This Agreement shall take effect on the Effective Date and shall continue in full force and effect for a period
of whichever is longer: a) five (5) years or b) the completion of the obligations of the Parties under this Agreement, unless earlier terminated in accordance with this Section 11. 

 

	 	11.2.	 Either Foundation or Kazia may terminate this Agreement immediately upon written notice to the other Party if
the other Party becomes insolvent, or if proceedings are instituted against the other Party for reorganization or other relief under any bankruptcy law, or if any substantial part of the other party’s assets come under the jurisdiction of a
receiver or trustee in an insolvency proceeding authorized by law. 

  

	 	11.3.	 Either Party may terminate this Agreement at any time, in whole or in part, with or without cause, upon
(a) giving at least thirty (30) days written notice to the other Party or (b) immediately giving written notice to the other Party if termination is for patient safety or regulatory reasons, including but not limited to a request from
NCI, the FDA, or other regulatory authority. 

  
 9 

	 	11.4.	 Foundation may terminate this Agreement immediately upon written notice to Kazia if: (i) Foundation
receives notice from the FDA or NCI that it requires that the corresponding Study be terminated; (ii) or if Foundation funding from the NCI is discontinued, reduced, denied, or otherwise unavailable. 

 

	 	11.5.	 Foundation may terminate this Agreement if Kazia materially breaches this Agreement and fails to cure the
breach within thirty (30) days after receipt of written notice from Foundation, such notice specifying in detail the nature of the breach. Kazia may terminate this Agreement if Foundation materially breaches this Agreement and fails to cure the
breach within thirty (30) days after receipt of written notice from Kazia, such notice specifying in detail the nature of the breach. 

  

	12.	 EFFECT OF TERMINATION 

 

	 	12.1.	 Upon receipt of notice of termination of this Agreement from Kazia or provision of notice of termination by
Foundation, Foundation and Participating Sites shall use reasonable efforts to avoid incurring any additional costs to Kazia in connection with the Study. Foundation shall be compensated in accordance with Section 4 for activities performed in
accordance with this Agreement up to the effective date of termination. If, upon the effective date of termination, Kazia has advanced funds which have not been applied to any non-cancellable costs for the
Study, Foundation shall repay such funds within sixty (60) days of the effective date of termination. Per the attached Exhibit A, Funding and Payment Schedule, both Parties recognize that advanced funds are limited herein to the upon contract
execution milestone in Annex A. 

  

	 	12.2.	 Upon termination or expiration of this Agreement, all unused Study Drag at Foundation’s designee,
McKesson, shall be promptly returned to Kazia’s nominated US storage facility, at Kazia’s reasonable expense, or, at Kazia’s option, Foundation will arrange destruction and supply written confirmation of material destruction,
including lot numbers and quantities destroyed. However, Foundation will retain sufficient Study Drug to treat all patients enrolled at the time of termination or expiration. After termination of this Agreement for any reason, all parties shall
continue activities under this Agreement solely as deemed necessary by mutual agreement of the Parties and NCI based on reasonable medical judgment to protect the health and safety of the subjects participating in the Study. Kazia shall pay
Foundation for any non-cancellable costs incurred prior to the date of termination. 

  

	 	12.3.	 The obligations of any provisions, such as Confidentiality and Intellectual Property, that by their nature
survive teimination or expiration of this Agreement shall survive any termination or expiration of this Agreement. 

  

	13.	 INDEMNIFICATION 

 

	 	13.1.	 Kazia will indemnify and hold harmless Foundation, the Alliance, and their respective directors, officers,
employees, Alliance Participating Investigators and Participating Sites, agents, and volunteers (collectively, “Alliance Indemnitees”) from any and all liability, loss (including reasonable attorneys’ fees), costs or damage
(collectively, “Damages”) they may suffer as the result of third party claims (provided that such third parties will not include any claim by an Alliance Indemnitee), demands or actions ( each a “Claim”) against them (i) to
the extent such Damages arise out of defects in the design or manufacture of the Study Drug or the Study Drug not being in accordance with its specifications at the date of delivery to Foundation’s designee, or (ii) to the extent arising
from Kazia’s breach of this Agreement, or (iii) to the extent arising from the negligence or willful misconduct or omissions of Kazia except to the extent any Damages arise from, or are alleged to arise from: 

 

	 	13.1.1.	 the failure by Alliance Indemnitees, Participating Investigators or Participating Sites to use the Study Drag
in accordance with the Protocol; or 

  

	 	13.1.2.	 the failure of any Alliance Indemnitee, Participating Investigator or Participating Site to strictly adhere to
the terms of the Protocol; or 

  

	 	13.1.3.	 negligence or willful misconduct on the part of Alliance Indemnitees, Participating Investigators or
Participating Sites; or 

  
 10 

	 	13.1.4.	 a breach of this Agreement or any applicable federal, state or local law by Alliance Indemnitees, Participating
Investigators or Participating Sites; or 

  

	 	13.1.5.	 a claim related to a drug or product other than Study Drug; or 

 

	 	13.1.6.	 any other act or omission of the Alliance Indemnitees, Participating Investigators or Participating Sites

  

	 	13.2.	 The Foundation shall, and shall cause the Alliance to: (a) provide written notice to Kazia of any Claim
arising out of the indemnified activities as soon as reasonably possible after the Alliance Indemnitee has knowledge of such Claim; (b) permit Kazia to assume responsibility to investigate, prepare for and defend against any such Claim;
(c) assist Kazia, at Kazia’s reasonable expense, in the investigation of, preparation for and defense of any such Claim; and (d) not compromise or settle such Claim without Kazia’s written consent. Kazia shall not settle a Claim,
in any manner without such Alliance Indemnitee’s prior written consent. 

  

	 	13.3.	 Foundation will indemnify and hold harmless Kazia and its directors, officers, employees and agents, from any
and all Damages they may suffer as the result of any Claim against them (i) to the extent such Damages arise out of conduct of the Study by any Alliance Indemnitee, or, (ii) to the extent arising from Foundation’s breach of this
Agreement, or (iii) to the extent arising from the negligence or willful misconduct of Foundation, except to the extent any Damages arise from, or are alleged to arise from any act or omission of Kazia. 

 

	14.	 INSURANCE 

Each Party hereto represents and warrants to the other that it currently carries and will continue to carry commercially reasonable levels of insurance to meet
its obligations hereunder. 
  

	15.	 REPRESENTATIONS, WARRANTIES. AND COVENANTS 

 

	 	15.1.	 Foundation and Kazia represent and warrant that that they are not individually a party to, and covenant that
during the term of this Agreement it shall not enter into, any agreement to provide services to another party which would in any way materially impair its ability to complete their obligations under this Agreement in a timely fashion and in
accordance with terms hereunder. 

  

	 	15.2.	 Foundation represents and warrants that: (i) it is not currently involved in any litigation, and is
unaware of any pending litigation proceedings, relating to Foundation’s role in the conduct of a clinical trial for any third party; and (ii) it has not received any warnings from the FDA (or any equivalent oversight body in a country
other than the United States) relating to services it has provided to third parties during the conduct of a clinical trial. 

  

	16.	 USE OF PARTIES’ NAMES; PUBLICITY 

No Party shall use (or have used on its behalf) another Party’s name, or the names of another Party’s employees, symbols, or trademarks in any
advertising, sales promotional material, or press release without prior written permission of the other Party, except to the extent such disclosure is necessary for: (a) regulatory filings, including filings with the U.S. Securities and
Exchange Commission or the FDA (or any equivalent oversight body in a country other than the United States); (b) prosecuting or defending litigation; (c) complying with Applicable Law; and (d) in publishing information regarding the
existence of, or results of, the Study in compliance with Section 9 of this Agreement. Except as otherwise permitted under this Agreement, a Party shall not originate any publicity, news release or other public announcement, written or oral,
whether to the public press or otherwise, relating to this Agreement, any Protocol, or any Study conducted hereunder without the other Party’s prior written consent. 

  
 11 

	17.	 INDEPENDENT CONTRACTOR 

The relationship between Kazia and Foundation is that of independent contractors. Foundation is not the partner, joint venturer, or agent of Kazia and
Foundation does not have the authority to make any statement, representation, commitment, or take action of any kind that purports to bind Kazia without Kazia’ prior written authorization. Kazia is not the partner, joint venturer, or agent of
Foundation, and Kazia does not have the authority to make any statement, representation, commitment, or take action of any kind that purports to bind Foundation without their prior written authorization. 

 

	18.	 NOTICES 

All notices under this Agreement shall be deemed to be duly given and received: (a) upon personal delivery to the appropriate address(es) below;
(b) ten (10) days after the date of mailing to the address(es) below when sent via registered or certified U.S. mail, return receipt requested, postage prepaid or by first-class mail. Notices pertaining to this Agreement shall be sent to: 

IF TO FOUNDATION: 
 Alliance For Clinical Trials in
Oncology Foundation Attn: Director - Contracts Administration Department 
 Address:125 S. Wacker Drive, Suite 1600 Chicago, TL 60606 

IF TO KAZIA 
 Name: Dr Jeremy Simpson 

Address: L24, Three International Towers, 300 
 Barangaroo Avenue,

 Sydney, NSW 2000 
  

	19.	 ASSIGNMENT 

This Agreement may not be assigned by operation of law or otherwise, in whole or in part, by any Party to any third party (other than to an Affiliate) without
the other Party’s prior written consent. To the extent permitted above, this Agreement shall be binding upon and inure to the benefit of the Parties and their permitted successors and assigns. Any attempted assignment of this Agreement not in
compliance with this Section 19 shall be null and void. 
  

	20.	 SEVERABILITY 

If any provision(s) of this Agreement should be held by a court of competent jurisdiction to be illegal or unenforceable in any respect, the legality and
enforceability of the remaining provisions of this Agreement shall not be affected, to the extent consistent with the intent of the parties as evidenced by this Agreement as a whole. The parties shall make a good faith effort to replace any such
provision with a valid and enforceable one such that the objectives contemplated by the parties when entering this Agreement may be realized. 
  

	21.	 WAIVER MODIFICATION OF AGREEMENT 

No waiver, amendment, or modification of any of the terms of this Agreement shall be valid unless in writing specifically referencing this Agreement and signed
by authorized representatives of all Parties. Failure by a Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights, nor shall a waiver by a Party in one or more instances be construed as constituting a
continuing waiver or as a waiver in other instances. 
  

	22.	 FORCE MAJEURE 

A Party shall not be deemed to have breached this Agreement for failure to perform its obligations under this Agreement to the extent such failure results from
any inclement weather, fire, flood, act of God, terrorist act, earthquake or any other cause which could not have been reasonably foreseen by such Party, was beyond the reasonable control of such Party, and which does not result from the negligence
or willful misconduct of such Party. If a force majeure event occurs, the Party unable to perform shall promptly notify the other Party of the occurrence of such event, and, promptly thereafter, the Parties shall discuss the circumstances relating
thereto. The Party unable to perform shall (i) provide reasonable status updates to the other Party from time to time, (ii) use commercially reasonable efforts to mitigate any adverse consequences arising out of its failure to perform and
(iii) resume performance as promptly as possible. In the event of any such force majeure event, the Parties may, in their discretion, revise or amend this Agreement by changing the performance period and other provisions, as appropriate by
mutual written agreement. 

	23.	 GOVERNING LAW 

This Agreement shall be governed by and interpreted in accordance with the laws of the State of Illinois without giving effect to any choice of law principles
that would require the application of the laws of a different state. Any claim or controversy arising out of or related to this Agreement or any breach hereof shall be submitted to a court of applicable jurisdiction in the State of Illinois, and
each Party hereby consents to the jurisdiction and venue of such court. 
  

	24.	 ENTIRE AGREEMENT 

This Agreement and any Exhibits hereto represent the entire and integrated agreement among the Parties and supersedes all prior negotiations, representations
or agreements, either written or oral, regarding its subject matter. 
  

	25.	 COUNTERPARTS 

This Agreement may be executed in any two or more counterparts, each of which, when executed, will be deemed to be an original and all of which together will
constitute one and the same document. Facsimile signatures and signatures transmitted via PDF will be treated as original signatures. 
  

	26.	 AUTHORITY 

The persons executing this Agreement on behalf of each Party represents that they have the full power and authority to enter into this Agreement on behalf of
the persons or entities they are signing on behalf of. Faxed, “docusigned”, and scanned copies of original signatures shall be deemed as effective as original signatures. 

 

	27.	 MISCELLANEOUS 

Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, the use of any gender will be
applicable to all genders, and the word “or” are used in the inclusive sense. When used in this Agreement, “including” means “including without limitation”. All section headings are for reference only and shall not be
used to interpret this Agreement. The official text of this Agreement, any notice given or accounts or statements required by this Agreement, and any dispute proceeding related to or arising hereunder, will be in English. In the event of any dispute
concerning the construction or meaning of this Agreement, reference will be made only to this Agreement as written in English and not to any other translation into any other language. 

  
 13 

 In Witness Whereof, the Parties have caused this Agreement to be executed in their names as their official
acts by their respective representatives, each of whom is duly authorized to execute the same. 
  

			
	Alliance for Clinical Trials Foundation
		
	By:	 	 /s/ Trinidad Ajazi

	Title:	 	Foundation Secretary
	Date:	 	June 26, 2019

  

			
	Kazia Therapeutics Limited
		
	By:	 	 /s/ James Garner

	Title:	 	Director
	Date:	 	June 26, 2019

  

			
	By:	 	 /s/ Kate Hill

	Title:	 	Company Secretary
	Date:	 	June 26, 2019

  
 14 

 ANNEX A - SOW and BUDGET 

Statement of Work 

A071701 
  

	I.	 Scope 

This document constitutes a Statement of Work (SOW) for work to be performed by Massachusetts General Hospital Cancer Center and McKesson
Clinical Research Services on behalf of the Alliance for Clinical Trials in Oncology Foundation. 
 Study: A071701 -
Genomically-guided trial in brain metastases 
 Study Drug: GDC-0084 

Planned Total Enrollment: 69 patients 
  

	II.	 Deliverables 

  

	 	A.	 Massachusetts General Hospital Cancer Center: Massachusetts General Hospital personnel will conduct the
snap assays on 190 patients for genotype screening. 

  

	 	B.	 McKesson Clinical Research Services: McKesson will handle drug supply and distribution of the study
drug. Fees include costs for project start-up, study drug storage & inventory management, study drug distribution & site communications, & project closeout. 

 

	 	C.	 Non-Standard of Care Procedures: 

 

	 	•	 	 EKG: EKG/ECG tests will be performed by sites on all patients (estimated 7 per patient) at baseline
visit, every 8 weeks (2 cycles) from start of treatment, and end of treatment totaling 483 tests. 

  

	 	•	 	 Cholesterol, serum or whole blood, total: Cholesterol tests will be performed by sites on all
patients (estimated 4 per patient) at baseline visit and every 4 cycles totaling 276 tests. 

  

	 	•	 	 Triglycerides: Triglyceride tests will be performed by sites on all patients (estimated 4 per
patient) at baseline visit and every 4 cycles totaling 276 tests. 

 Budget and Milestone Payment Schedule 

Budget 
  

							
	Study Number	 	A071701
		
	Study Title	 	Genomically-guided trial in brain metastases
				
	 	 	 Description
	 	 Cost
	 	 Assumptions

	Alliance Screening (Massachusetts General Hospital Cancer Center)	 		 		 	
		 	Snap assay for screening	 		 	Estimated 1 per patient (190 patients)
	Drug Supply and Distribution (McKesson)	 		 		 	
		 	Start up fee	 		 	
		 	Storage/Inventory	 		 	Estimated 36 months.
		 	Shipping	 		 	Estimated 2 per patient totaling 138 shipments.
		 	Close out Fee	 		 	
	Additional Procedures	 		 		 	
		 	Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report	 		 	Estimated 7 per patient (Baseline, every 8 weeks (2 cycles) from start of treatment, and end of treatment) totaling 483.
				
		 	Cholesterol, serum or whole blood, total	 		 	Estimated 4 per patient (Baseline and every 4 cycles) totaling 276.
				
		 	Triglycerides	 		 	Estimated 4 per patient (Baseline and every 4 cycles) totaling 276.
	Total	 		 		 	
			
	 Sample Size Key
	 	 	 	 
	Total N for screening W/10% screening buffer	 	190	 	
	N =	 	69	 	

 Milestone Payment Schedule 
  

					
	 Payment Milestone
	  	Payment	 
	 Upon Contract Execution (Approx. 20% or equivalent to first 14 patients)
	  	 	            	 
	 Per Quarterly Accrual (14th patient up to 69 patients); patient enrolled
	  			
	 Total Balance:
	  			

 ANNEX B - CTEP IP OPTION 

A. The IP Option described in this Section A would apply to inventions that would be described in patent disclosures that claim the use and/or the composition
of the Agent(s) and that are conceived or first actually reduced to practice pursuant to clinical or non-clinical studies utilizing the NCI CTEP provided Agent(s)(“Section A Inventions”): 

Institution agrees to grant to Collaborator(s): (i) a royalty-free, worldwide, non-exclusive license for commercial
purposes with the right to sub license to affiliates or collaborators working on behalf of Collaborator for Collaborator’s development purposes; and (ii) a time limited first option to negotiate an exclusive, or co-exclusive, if applicable, world-wide, royalty bearing license for commercial purposes, including the right to grant sub licenses, subject to any rights of the Government of the United States of America, on terms
to be negotiated in good faith by the Collaborator(s) and Institution. If Collaborator accepts the non-exclusive commercial license, the Collaborator agrees to pay all out of pocket patent prosecution and
maintenance costs which will be pro-rated and divided equally among all licensees. If Collaborator obtains an exclusive commercial license, in addition to any other agreed upon licensing arrangements such as
royalties and due diligence requirements, the Collaborator agrees to pay all out of pocket patent prosecution and maintenance costs. Collaborator(s) will notify Institution, in writing, if it is interested in obtaining a commercial license to any
Section A Invention within three (3) months of Collaborator’s receipt of a patent application or six (6) months of receipt of an invention report notification of such a section A invention. In the event that Collaborator fails to so
notify Institution, or elects not to obtain an exclusive license, then Collaborator’s option expires with respect to that Section A Invention, and Institution will be free to dispose of its interests in accordance with its policies. If
Institution and Collaborator fail to reach agreement within ninety (90) days, (or such additional period as Collaborator and Institution may agree) on the terms for an exclusive license for a particular Section A Invention, then for a period of
three (3) months thereafter Institution agrees not to offer to license the Section A Invention to any third party on materially better terms than those last offered to Collaborator without first offering such terms to Collaborator, in which
case Collaborator will have a period of thirty (30) days in which to accept or reject the offer. If Collaborator elects to negotiate an exclusive commercial license to a Section A Invention, then Institution agrees to file and prosecute patent
application(s) diligently and in a timely manner and to give Collaborator an opportunity to comment on the preparation and filling of any such patent application(s). Notwithstanding the above, Institution is under no obligation to file or maintain
patent prosecution for any Section A Invention. 
 For all Section A Inventions, regardless of Collaborator’s decision to seek a commercial license,
Institution agrees to grant Collaborator a paid-up, nonexclusive, royalty-free, world-wide license for research purposes only. Institution retains the right to make and use any Section A Invention for all non-profit research, including for educational purposes and to permit other educational and non-profit institutions to do so. 

B. The IP Option described in this Section B would apply to inventions not covered by Section A, but are nevertheless conceived or first actually reduced to
practice pursuant to clinical or non-clinical studies utilizing the CTEP-provided Agent(s). It also applies to inventions that are conceived or first actually reduced to practice pursuant to NCI CTEP-approved
studies that use non-publicly available clinical data or specimens from patients treated with the CTEP-provided Agent (including specimens obtained from NCI CTEP-funded tissue banks) (“Section B
Inventions”): 
 Institution agrees to grant to Collaborator(s): (i) a paid-up nonexclusive, nontransferable,
royalty-free, world-wide license to all Section B Inventions for research purposes only; and (ii) a nonexclusive, royalty-free, world-wide license to (a.) disclose Section B Inventions to a regulatory authority when seeking marketing
authorization of the Agent, and (b.) disclose Section B Inventions on a product insert or other promotional material regarding the Agent after having obtained marketing authorization from a regulatory authority. Notwithstanding the above,
Institution is under no obligation to file or maintain patent prosecution for any Section B Invention. 
 C. The IP Option described in this Section C would
apply to inventions made by Institution’s investigator(s) or any other employees or agents of Institution, which are or may be patentable or otherwise protectable, as a result of research utilizing the CTEP-provided Agent(s), unreleased or non-publicly available clinical data or Agent treated specimens outside the scope of approval granted by the NCI CTEP (Unauthorized Inventions): 

Institution agrees, at Collaborator’s request and expense, to grant to Collaborator a royalty-free exclusive or co-exclusive license to Unauthorized
Inventions. Institution will retain a non-exclusive, non-sub-licensable royalty free license to practice the invention for
research use purposes. 

  
 17 

 D. Institution Notification 

Institution agrees to promptly and confidentially notify NCI CTEP (NCICTEPpubs@mail.nih.gov) and Collaborator(s) in writing of any Section A Inventions,
Section B Inventions, and Unauthorized Inventions upon the earlier of: (i) any submission of any invention disclosure to Institution of a Section A, Section B, or Unauthorized Invention, or (ii) the filing of any patent applications of a
Section A, Section B, or Unauthorized Invention. Institution agrees to provide a copy of either the invention disclosure or the patent application to the Collaborator and to NCI CTEP which will treat it in accordance with 37 CFR Part 401. These
requirements do not replace any applicable reporting requirements under the Bayh-Dole Act, 35 USC 200-212, and implementing regulations at 37 CFR Part 401. 

 ANNEX C - Study Drug Responsibilities 

 

											
	 Study Drug Responsibilities

GDC-0084 15mg Capsules - Phase 2 Clinical Study Use
	  

 

	  
 Background & Scope:

 
 (i) Foundation plans to Sponsor a Phase 2
clinical study using GDC-0084 15mg capsules, with study drug responsibilities as indicated below.
  

(ii)  Kazia will supply to the Foundation’s nominated US storage depot, GMP manufactured, primary
packed and labelled study drug for Phase 2 clinical trial use in the US. Kazia responsibilities as indicated below.
	 
  

   

    

				
	 #
	  	 Responsibility
	  	Kazia	 	  	Foundation	 
				
	 1
	  	Study Drug: Supply of GMP manufactured, primary packed and labeled GDC-0084 15mg capsules with supporting GMP documentation (e.g. manufacturers CoA). In addition to the labelling, each
bottle of study drug is also identified with the lot number printed on the base of the bottle	  	 	X	 	  			
				
	 2
	  	Study Drug: the required study drug label text will be agreed between the parties	  	 	X	 	  	 	X	 
				
	 3
	  	Retest Date & Storage Conditions: Provision of retest date and storage conditions for the study drug supplied	  	 	X	 	  			
				
	 4
	  	Ordering: Requests for study drug will be provided to Kazia in writing	  				  	 	X	 
				
	 5
	  	Shipping: Will ship study drug to the Foundation nominated US Depot, accompanied by relevant paperwork (e.g. packing list)	  	 	X	 	  			
				
	 6
	  	Receipt & Labeling: Foundation’s nominated US depot will receive and store study drug for clinical study use	  				  	 	X	 
				
	 7
	  	Release & Distribution of Study Drug: Responsibility for release/distribution of labeled study drug for Phase 2 clinical use in the US	  				  	 	X	 
				
	 8
	  	Product Defects / Product Complaints: will promptly notify the other party if a Quality Defect is observed or reported (e.g. damage to capsules or primary packaging)	  	 	X	 	  	 	X	 
				
	 9
	  	Product Recall: will notify Foundation in the event of a Product Recall and both parties will work together as may be required to coordinate the Recall and notify the relevant regulatory authorities [Note: Product Recall may
also be referred to as “stock recovery” in US as the Sponsor exerts direct control over the drug].	  	 	X	 	  			
				
	 10
	  	Returns & Destruction: The parties will liaise regarding the management of any drug stored at Foundation’s nominated US depot, McKesson, that is no longer required for the planned study. The anticipated options
are (i) return the drug to Kazia’s nominated US depot (at Kazia expense) or (ii) Foundation, through its designated US depot, McKesson, manage destruction and provide Kazia with a destruction certificate detailing lot numbers and
quantities of study drug destroyed.	  				  			

  
 19EX-4.14

 Exhibit 4.14 
  

 
 

 
  
  

Master Clinical Trial 
 Agreement 

Kazia Laboratories Pty Ltd 
 St. Jude Children’s Research Hospital,
Inc. 
  
  

 
  
 Kazia
Therapeuitcs Limited ABN 37 063 259754 
 PO Box 2333 Horns by Westfield1635 NSW Australia 

T+61 29476 0344 F+61 2 9476 0388 
 www.kaziatherapeuitcs.com 

 Table of contents 
  

							
	 	 	 
	 1.
	 	Definitions and Interpretation	  	 	3	 
			
	 2.
	 	Appointment	  	 	7	 
			
	 3.
	 	Conduct of the Project	  	 	8	 
			
	 4.
	 	Modification of Services	  	 	8	 
			
	 5.
	 	Test Materials	  	 	8	 
			
	 6.
	 	Payment	  	 	9	 
			
	 7.
	 	Taxes	  	 	10	 
			
	 8.
	 	Warranties	  	 	10	 
			
	 9.
	 	ConfidentiaIity	  	 	10	 
			
	 10.
	 	Privacy	  	 	12	 
			
	 11.
	 	Retention of Records	  	 	13	 
			
	 12.
	 	Reporting Obligations	  	 	13	 
			
	 13.
	 	Access	  	 	13	 
			
	 14.
	 	Insurance	  	 	14	 
			
	 15.
	 	Intellectual Property	  	 	14	 
			
	 16.
	 	Data Use	  	 	14	 
			
	 17.
	 	Publications	  	 	14	 
			
	 18.
	 	Use of Name and Promotional Activities	  	 	15	 
			
	 19.
	 	Liability	  	 	15	 
			
	 20.
	 	Termination	  	 	15	 
			
	 21.
	 	Consequences of Expiry or Termination	  	 	16	 
			
	 22.
	 	Assignment	  	 	16	 
			
	 23.
	 	Independent Contractors	  	 	17	 
			
	 24.
	 	Notices	  	 	17	 
			
	 25.
	 	Dispute Resolution	  	 	18	 
			
	 26.
	 	Entire Agreement	  	 	19	 
			
	 27.
	 	Force Majeure	  	 	19	 
			
	 28.
	 	No Waiver	  	 	19	 
			
	 29.
	 	Severability	  	 	19	 

							
	30.	 	Survival of Provisions	  	 	20	 
			
	31.	 	Choice of Law	  	 	20	 
		
	 Schedule 1
	  	 	22	 
	 Contract Details
	  	 	22	 
		
	 Schedule 2
	  	 	23	 
	 List of Kazia and Subsidiaries
	  	 	23	 
		
	 Schedule 3
	  	 	24	 
	 Template Work Order
	  	 	24	 

			
	Title	  	Master Clinical Trial Agreement
		
	Date	  	19 November 2017
		
	Parties	  	Kazia Laboratories Pty Ltd (ABN 37 063 259 754) of Suite 502, Level 5, 20 George Street, Horns by, NSW 2077 (Kazia)
		
		  	St. Jude Children’s Research Hospital, Inc. of 262 Danny Thomas Place, Memphis, TN 38002 (the Research Organisation)

 Recitals 
  

	A	 Kazia is a global biotechnology company engaged in the research and development of therapeutic products or devices for
patients with cancer. 

  

	B	 The Research Organisation provides scientific research services, including: basic
pre-clinical research, clinical research and/or scientific consulting. 

  

	C	 The Parties wish to agree to master terms to govern the relationship between them under which Kazia may, from time to
time, request services from the Research Organisation and the Research Organisation may provide services to Kazia. 

  

	D	 This Agreement sets out the master terms and conditions under which the Research Organisation will perform certain
clinical trials. 

  

	E	 An individual Work Order under this Master Services Agreement will describe the services to be provided by the Research
Organisation to conduct specific Projects and Services. 

 Operative provisions 

 
  
  

	1.	 Definitions and Interpretation 

Definitions 
  

	 	1.1	 In this Agreement: 

Agreement means this Master Services Agreement, including all schedules, appendices and annexures. 

Applicable Law means all applicable federal, state and local laws, regulations, guidelines and rules, applicable to the performance of a Project
including without limitation all applicable laws and regulations related to import/ export control, use and distribution of tissue samples, anti-bribery and anti-terrorism. 

Background Intellectual Property means, in respect of a Party, any Works provided by that Party in connection with this Agreement. 

Biological Samples means diagnostic tests, data, and bodily fluids (e.g., blood, urine, saliva, tissue, sera), bone marrow, tumor samples, tissue
biopsies, and other biological samples and materials derived therefrom. 

  
 3 

 Business Day means a day that is not a Saturday, Sunday or a public holiday or bank holiday in
Sydney or the United States. 
 Claim means any claim made (whether in the form of an allegation, demand, suit, action or other proceeding of
any kind) under or in connection with this Agreement or its subject matter, whether arising under contract (including under any warranty or indemnity or any other breach, actual or anticipatory including repudiation), in equity, in restitution,
negligence or any other tort, strict liability, under statute or otherwise at all. 
 Commencement Date means the date set out in Schedule 1.

 Confidential Information means all information related to the Project imparted by either Party to the other Party in the course of the
performance of this Agreement, whether: 
  

	 	(a)	 oral, written, recorded or stored by electronic, magnetic, electromagnetic or other form, processed or otherwise or in a
machine readable form; 

  

	 	(b)	 any improvements, modifications or developments to Background Intellectual Property provided by a Party; or

  

	 	(c)	 translated from the original form, recompiled, made into a compilation, partially copied, modified, updated or otherwise
altered, 

 except to the extent that: 
  

	 	(a)	 the information is or becomes in the public domain otherwise than as a result of the default of the receiving Party;

  

	 	(b)	 the receiving Party can demonstrate that the information was known to it prior to the disclosure by the disclosing
Party; 

  

	 	(c)	 the information has been disclosed to the receiving Party without restriction by a third party and without any breach of
confidentiality by the third party, to the best of the receiving Party’s knowledge; or 

  

	 	(d)	 the information is independently developed by the receiving Party without reference to the Confidential Information
provided by the disclosing Party. 

 Force Majeure Event means an event relating to a Party which: 

 

	 	(a)	 was not contemplated by that Party and could not have reasonably been foreseen by that Party at the Commencement Date;

  

	 	(b)	 is completely outside the control of that Party, or its Personnel; 

 

	 	(c)	 is not an event or occurrence contemplated by, or referred to in, this Agreement; 

 

	 	(d)	 is not caused by the other Party or its Personnel; and 

 

	 	(e)	 is not a result of industrial action or strike. 

Human Subject means a living individual about whom an Investigator conducting research obtains: 

 

	 	(a)	 data through intervention or interaction with the individual; or 

 

	 	(b)	 Identifiable Personal Information. 

  
 4 

 Informed Consent means the informed consent form specific for each Proposal and prepared by the Research Organisation according to the requirements of Applicable Laws. 

Intellectual Property includes all
copyright and neighbouring rights (including rights in relation to phonograms and broadcasts), all rights in relation to inventions (including patent rights), plant varieties, registered and unregistered trade marks (including service marks),
registered and unregistered designs, and circuit layouts, and all other rights resulting from intellectual activity in the industrial, scientific, literary or artistic fields including as defined in Article 2 of the Convention Establishing the World
Intellectual Property Organisation of July 1967. 
 Identifiable Personal Information
means Human Subject identifiable data no matter how obtained, including from medical records or attached to Human Subject specimens, to be obtained prospectively or from stored medical records,
specimens or otherwise, that can be linked to individual human beings, either directly or indirectly through codes. 
 Institutional Review Board (IRB) means a body set up to review clinical investigations carried out by the Research Organisation. 

Investigator means the person or entity
responsible for the performance of the research or clinical trial at a trial site, except that if the research or clinical trial is performed by a team of individuals at a trial site, the investigator is the responsible leader of the team and may be
called the principal investigator. 
 Party means a Party to this Agreement, and in relation to Kazia, includes any affiliate of Kazia listed in Schedule 2. 

Permitted Purpose means the sole purpose
of performing the Services under this Agreement and each Work Order. 
 Permitted
Recipient means any third party, including employees and agents of the party receiving Confidential Information (the “Receiving Party”) to whom the Receiving Party discloses the
disclosing Party’s Confidential; provided however that Confidential Information shall only be disclosed to third parties with a need to know the information and all such third parties shall be informed of the confidential nature of the
Confidential Information and shall be bound by obligations of confidentiality, non-use, and non-disclosure that are no less stringent than those contained herein. 

Personnel means a Party’s employees,
contractors, guest researchers, students or other representatives. 
 Project means an individual study, project or consultation forming part of the Services and defined in a Work Order, including but not limited to a pre-clinical or clinical study, project or other scientific
examination involving the collection of data. 
 Project Budget means the budget associated with a Project associated with a Project, as set out in a Work Order. 
 Proposal means a formal, detailed description of a Project setting out the objective, design, methodology, statistical considerations, and
organization of that study or research. 
 Retained Samples means any remaining portions of already-collected Biological Samples, exclusive of the portion of Biological Samples required for the Clinical Trial. 

Services means the tasks or services to
be performed by the Research Organisation in accordance with this Agreement or in a Work Order. 

  
 5 

 Term means the term of this Agreement as set out in Schedule 1. 

Test Materials in respect of a Project, means all compounds, devices, materials or other substances meeting relevant specifications that are
necessary to enable the Research Organisation to perform the Project. 
 Work Order means a written order substantially in the form set out in
Schedule 3 to this Agreement agreed between the Parties which: 
  

	 	(a)	 describes the nature and scope of the Services requested to be provided by the Research Organisation in respect of a
particular Project performed by the Research Organisation for Kazia; 

  

	 	(b)	 sets out the schedule of work to be performed or consulting Services to be provided during the course of a particular
Project performed by the Research Organisation for Kazia; 

  

	 	(c)	 specifies the price, fees and payment schedule for the requested Services, and 

 

	 	(d)	 specifies any modifications of the terms of this Agreement that are applicable to the Services. 

Works means all drawings, specifications, processes, techniques, samples, specimens, prototypes, designs, research and development results, test
results, and other technical and scientific information and Intellectual Property which is made available for the Project by a Party. 
 Interpretation 

 

	 	1.2	 In this Agreement, unless the context requires another meaning, a reference: 

 

	 	(a)	 to the singular includes the plural and vice versa; 

 

	 	(b)	 to a gender includes all genders; 

 

	 	(c)	 to a document (including this Agreement) is a reference to that document (including any schedules and annexures) as
amended, consolidated, supplemented, novated or replaced; 

  

	 	(d)	 to an agreement includes any undertaking, representation, deed, agreement or legally enforceable arrangement or
understanding whether written or not; 

  

	 	(e)	 to an item, recital, clause or Schedule is to an item, recital, clause or Schedule of or to this Agreement;

  

	 	(f)	 to a notice means a notice, approval, demand, request, nomination or other communication given by one Party to another
under or in connection with this Agreement; 

  

	 	(i)	 to a person (including a Party) includes: 

 

	 	(ii)	 an individual, company, other body corporate, association, partnership, firm, joint venture, trust or government agency;

  

	 	(iii)	 the person’s successors, permitted assigns, substitutes, executors and administrators; and 

  
 6 

	 	(iv)	 a reference to the representative member of the GST group to which the person belongs to the extent that the
representative member has assumed rights, entitlements, benefits, obligations and liabilities which would remain with the person if the person were not a member of a GST group; 

 

	 	(g)	 to proceedings includes litigation, arbitration and investigation; 

 

	 	(h)	 to a judgment includes an order, injunction, decree, determination or award of any court or tribunal;

  

	 	(i)	 to time is to US central daylight savings time; 

 

	 	(j)	 to currency or “$” is to US dollars; and 

 

	 	(k)	 the words “including” or “includes” means “including, but not limited to”, or
“includes, without limitation” respectively. 

  

	 	1.3	 Where a word or phrase is defined, its other grammatical forms have a corresponding meaning. 

 

	 	1.4	 Headings are for convenience only and do not affect interpretation of this Agreement. 

 

	 	1.5	 If a period will be calculated from, after or before a day or the day of an act or event, it will be calculated excluding
that day. 

  

	 	1.6	 The Agreement may not be construed adversely to a Party only because that Party was responsible for preparing it.

  

	 	1.7	 Except where expressly stated to the contrary, if there is an inconsistency between any one or more of documents
comprising this Agreement the document listed higher in the following list will prevail to the extent of the inconsistency: 

  

	 	(a)	 each Work Order; 

  

	 	(b)	 the Schedules; and 

  

	 	(c)	 the main body of this Agreement. 

 
  
  

	2.	 Appointment 

  

	2.1	 Kazia appoints the Research Organisation on a non-exclusive basis to conduct the
Projects as described in a Work Order. 

  

	2.2	 The Research Organisation agrees to provide the Services described in a Work Order and Kazia agrees to pay the Research
Organisation for those Services as provided for in the Work Order and this Agreement. 

  

	2.3	 Upon agreement between the Parties of the terms of a Work Order, a Work Order is incorporated in and becomes part of this
Agreement. 

  

	 	2.4	 This Agreement shall commence on the Commencement Date and continue for the Term unless otherwise terminated in
accordance with this Agreement. 

  

	2.5	 Kazia and the Research Organisation shall each appoint a representative to serve as the contact point for the management
and administration of this Agreement. Either Party can replace its representative at any time by notice in writing to the other Party. 

  
 7 

	2.6	 The Parties understand and agree that Work Orders may be entered into by any Affiliates of Kazia if explicit reference to
this Agreement is made in the relevant Work Order and Affiliate will be entitled to all the benefits and subject to all the obligations of this Agreement. 

  

	2.7	 With Kazia’s prior written consent, affiliated research institutions may enter into a participating site agreement
or a single study agreement with the Research Organisation to conduct the Services in accordance with the terms of the relevant Work Order. 

  

 
  

	3.	 Conduct of the Project 

  

	3.1	 The Parties shall comply with all Applicable Laws in performing their obligations under this Agreement.

  

	3.2	 The Research Organisation shall: 

 

	 	(a)	 conduct the Project and Services pursuant to the terms of this Agreement and in strict adherence to the relevant
Proposal; 

  

	 	(b)	 ensure that the Project is not initiated until and unless all governing regulatory authorities agree to the conduct of
the Project; and 

  

	 	(c)	 conduct the Project and Services with all due care and skill, including exerting diligent efforts consistent with
applicable professional and ethical standards and having due regard for the safety and protection of Project participants. 

  

 
  

	4.	 Modification of Services 

  

	4.1	 A Work Order may be amended from time to time with the written agreement of both Parties. 

 

	4.2	 If an amendment requires the Research Organisation to undertake additional or different work materially beyond the scope
of work already agreed between the Parties in a Work Order, the Research Organisation will notify Kazia of any additional costs associated with that additional or different work, and will not commence that work until the parties have executed an
amended Work Order. 

  

	4.3	 The Research Organisation will not deviate from a Work Order without Kazia’s prior written approval unless in an
emergency to protect the safety of Human Subjects participating in the Project and provided the Research Organisation has first used reasonable efforts to inform Kazia of the emergency and to consult with Kazia, if time permits, with regard to the
deviation. Notwithstanding anything herein to the contrary, nothing in this Agreement shall be construed as a restriction on Research Organisation’s ability to deviate from the Protocol in order to protect the health or safety of Human
Subjects; and Research Organisation shall retain final decision-making authority with regard to whether a deviation from the Protocol is necessary. 

  

 
  

	5.	 Test Materials 

  

	5.1	 To the extent specified in a Work Order, Kazia will provide, at no cost to the Research Organisation, sufficient amounts
of Test Materials for the purposes of the Project and will also provide data necessary to inform the Research Organisation of the stability, proper storage and safe handling requirements of the Test Materials. 

  
 8 

	5.2	 During and for a period of at least two years after the completion of each relevant Work Order, Kazia will promptly, but
no later than ten (10) days, notify the Research Organisation of the emergence of information impacting the health and safety of past or current Project participants or which influences the conduct of the Proposal including but not limited to
the safety results and information in site monitoring reports and data safety monitoring committee reports as required by the Proposal. In each case, the Research Organisation shall be free to communicate these findings to each Project participant
and the IRB. 

  

	5.3	 Unless otherwise specified in the Work Order, Kazia will cause Test Materials to be shipped properly packaged and
labelled directly to the Research Organisation or approved affiliated research institution. 

  

	5.4	 Kazia, for the purposes only of the Research Organisation providing the Services, represents and warrants:

  

	 	(a)	 that the Test Materials are manufactured and formulated, and pass control tests, in accordance with all applicable
regulations; 

  

	 	(b)	 that it has disclosed to Research Organisation and any applicable government authorities all material information
concerning Test Material safety, use, efficacy, and drug experience; 

  

	 	(c)	 that to the best of its knowledge after reasonable inquiry, use of the Test Material for the purposes contemplated
hereunder will not infringe third party intellectual property rights; and 

  

	 	(d)	 hazardous material packaging that it provides meets regulatory requirements for Research Organisation and other study
sites’ use as contemplated hereunder. 

  
  

 

	6.	 Payment 

  

	6.1	 The Parties will work in good faith to negotiate a payment schedule for each Work Order. 

 

	6.2	 Kazia will pay the Research Organisation as set out in the applicable Work Order and, unless otherwise agreed in the Work
Order, all invoices are due and payable and will be paid by Kazia within thirty (30) days of the date of invoice. 

  

	6.3	 The Research Organisation must present its invoices in respect of the Project in accordance with the timeframes specified
in each Work Order and associated Project Budget, and in a form reasonably required by Kazia. 

  

	6.4	 Kazia will reimburse for all pre-approved and reasonable travel and other
reasonable out of pocket expenses (as identified in the Project Budget or Work Order) incurred by the Research Organisation or its Personnel in performance of the Project provided the expenses are approved beforehand in writing or form part of a pre-approved Project Budget or Work Order. 

  

	6.5	 If a dispute arises between the Parties in respect of any part of an invoice, Kazia: 

 

	 	(a)	 must pay all undisputed parts of the invoice within the stipulated thirty (30) day period; 

 

	 	(b)	 must notify the Research Organisation promptly in writing of the particulars of the dispute; 

  
 9 

	 	(c)	 may withhold payment of the disputed part of the invoice provided that Kazia endeavours promptly and in good faith to
resolve the dispute, and 

  

	 	(d)	 if applicable and upon Kazia’s written request the Research Organisation may re-issue a new invoice to Kazia for the
undisputed portion. 

  
  

 

	7.	 Taxes 

  

	7.1	 All amounts payable under this Agreement are inclusive of all government taxes, levies, imposts, deductions, changes,
duties or withholding which are assessed, levied or imposed in connection with the Services. 

  

 
  

	8.	 Warranties 

  

	8.1	 The Research Organisation represents and warrants that: 

 

	 	(a)	 all persons performing the Project are subject to appropriate confidentiality obligations to enable the Research
Organisation to comply with its obligations under this Agreement; 

  

	 	(b)	 the Services performed by it will conform to the nature and scope of Services as agreed in the Work Order and all
Applicable Law; 

  

	 	(c)	 the Services will be fit for purpose and be provided with all due care and skill; and 

 

	 	(d)	 the performance of the Services by the Research Organisation will, to Research Organisation’s knowledge, not
infringe the Intellectual Property of any third party. 

 8.2 The Research Organisation is responsible for
obtaining and maintaining during the term of the Project all approvals and licences necessary for the performance of the Services and as required by Applicable Laws. 
  

 
  

	9.	 Confidentiality 

  

	9.1	 The Parties shall: 

  

	 	(a)	 treat as confidential and only access and use the disclosing Party’s Confidential Information solely for the
Permitted Purpose and not access, use, publish, disclose or permit the access, use, publication or disclosure of it for any other purpose or other than in accordance with this Agreement without the disclosing Party’s prior written approval;

  

	 	(b)	 only allow the Permitted Recipients to access or use the disclosing Party’s Confidential Information for the
Permitted Purpose; 

  

	 	(c)	 not use or exploit the disclosing Party’s Confidential Information for its own benefit (except as expressly
permitted by this Agreement) or to the competitive disadvantage of either Party or its affiliates; 

  

	 	(d)	 not, without the disclosing Party’s prior written consent, copy or reproduce any of the disclosing Party’s
Confidential Information for any purpose other than the Permitted Purpose. 

  
 10 

	 	(e)	 ensure that confidentiality is maintained in relation to the Confidential Information. 

 

	9.2	 The Parties’ obligations under this Agreement do not apply to the extent that the disclosure of Confidential
Information is required by: 

  

	 	(a)	 law; 

  

	 	(b)	 the requirements of any regulatory authority of competent jurisdiction; 

 

	 	(c)	 the rules of any stock exchange; 

 

	 	(d)	 any applicable accounting standards; or 

 

	 	(e)	 order by any court. 

  

	9.3	 If clause 9.2 applies, the Parties shall, subject to clause 9.4, prior to disclosure of the Confidential Information:

  

	 	(a)	 notify the disclosing Party; 

  

	 	(b)	 give the disclosing Party a reasonable opportunity to take steps to protect the confidentiality of the relevant
Confidential Information; 

  

	 	(c)	 consult with the disclosing Party with a view to agreeing in good faith on the form, content, timing and manner of
disclosure or use, including taking into account any actual basis the disclosing Party may have to prevent or restrict disclosure or use, so as to ensure that as far as possible the extent of use or disclosure is strictly limited to that required,
provided however that nothing in this Agreement shall be construed as a restriction on the receiving party’s ability to respond to and comply a required disclosure under applicable law, rule, or regulation; and 

 

	 	(d)	 immediately notify the person to whom the Confidential Information is to be disclosed or used by that it is Confidential
Information and is therefore subject to the terms of this Agreement. 

  

	9.4	 If either Party is not permitted by law to notify the other Party prior to disclosure of the Confidential Information,
the Party being asked to disclose the Confidential Information shall: 

  

	 	(a)	 as soon as possible after disclosure and to the extent permitted by law, notify the other Party; 

 

	 	(b)	 ensure that it only discloses Confidential Information to the extent necessary to comply with its obligations arising
under any of clauses 9.2(a) to 9.2(e); and 

  

	 	(c)	 immediately notify the person to whom the Confidential Information is to be disclosed or used by that it is Confidential
Information and is therefore subject to the terms of this Agreement. 

  

	9.5	 The Parties shall: 

  

	 	(a)	 establish and maintain effective security measures against unauthorised copying, use or disclosure of the Confidential
Information and against damage to or destruction of the Confidential Information; 

  

	 	(b)	 immediately notify the other Party of any actual or suspected unauthorised copying, use or disclosure of the Confidential
Information; and 

  
 11 

	 	(c)	 provide such assistance, as reasonably required by the disclosing Party, in relation to any proceedings that Party may
take against any person for unauthorised copying, use or disclosure of the Confidential Information. 

  

	9.6	 Subject to compliance with clause 9.7, the Parties may disclose the Confidential Information to Permitted Recipients if
the disclosure is necessary for the Permitted Purpose. 

  

	9.7	 Before disclosing any of the Confidential Information to any Permitted Recipient, the parties shall:

  

	 	(a)	 ensure that the Permitted Recipient agrees to be bound by, the obligations under this Agreement before the disclosure is
made or access to Confidential Information is allowed. 

  

	9.8	 The rights and obligations under this clause 9 will have a duration of five (5) years from the expiry or termination
of the last Work Order under this Agreement. For any Confidential Information that is still secret and confidential at the end of this period, if the disclosing Party requests and if the receiving Party concurs, this obligation of confidentiality
shall be extended for up to an additional two (2) years. This clause 9.89.8 will survive the expiry or termination of this Agreement. 

  

 
  

	10.	 Privacy 

  

	10.1	 The Research Organisation must obtain written consent of all Human Subjects for their participation in the Project only
if identifiable health information will be shared. 

  

	10.2	 The Research Organisation must do the following in relation to any Identifiable Personal Information provided to it by
Kazia under this Agreement or obtained in the course of performing the Services: 

  

	 	(a)	 only process, use or disclose Identifiable Personal Information as required for the purpose of performing its obligations
under the agreement; 

  

	 	(b)	 in the course of performing its obligations under the agreement, comply with the Health Insurance Portability and
Accountability Act (HIPAA) and the Privacy Act 1988 (Cth) and any privacy policy of Kazia as notified to the Research Organisation in writing (including amendments from time to time); 

 

	 	(c)	 except as provided in clause 10.l (a) or as required by law, not disclose any Identifiable Personal Information
without the written permission of Kazia; 

  

	 	(d)	 take all reasonable steps to prevent the misuse or loss of and unauthorised use, modification, disclosure of and access
to Identifiable Personal Information; 

  

	 	(e)	 upon the expiry or termination of this agreement, either destroy or return to Kazia (at Kazia’s option and request)
all Identifiable Personal Information (including any copies) and any record of the Identifiable Personal Information; and 

  

	 	(f)	 provide full cooperation and assistance to Kazia in allowing individuals to whom any Identifiable Personal Information
relates to have access to that information and exercise their rights to amend or make an annotation to the record of their Identifiable Personal Information. 

  
 12 

	10.3	 Each Party must immediately notify the other Party on becoming aware of: 

 

	 	(a)	 a complaint or an allegation of breach of applicable privacy laws by any person; or 

 

	 	(b)	 an investigation or enforcement action by a regulatory authority, in connection with the Project or this Agreement
(“Data Issue”). 

  

	10.4	 Each Party must cooperate reasonably with the other party in relation to any Data Issue, including providing all
information and assistance reasonably requested by a Party. Each Party shall consult with the other Party and allow the other Party the right to make representations in connection with any Data Issue before responding to any Data Issue.

  
  

 

	11.	 Retention of Records 

  

	11.1	 Not with standing requirements under Applicable Laws to retain medical files, the Research Organisation shall retain all
essential documents until at least 7 years after the expiry or termination of this Agreement, and shall not delete essential documents from its files without Kazia’s prior written consent. If Kazia requires record retention beyond seven
(7) years, records will be stored at Kazia’s sole expense. 

  

 
  

	12.	 Reporting Obligations 

  

	12.1	 The Research Organisation must provide Kazia with periodic reports relating to the Services on the date specified in the
Work Orders. 

  

	12.2	 The periodic reports must include all matters specified in the Work Orders. 

 
  
  

	13.	 Access 

  

	13.1	 The Research Organisation must keep true and accurate records including the scientific data produced during the conduct
of the Project, expense records and time sheets (if required) in respect of all activities undertaken for the purposes of this Agreement. 

  

	13.2	 Unless specified in a Work Order, Kazia shall not have access to any Identifiable Personal Information.

  

	13.3	 During the Term and for a period of one year thereafter , the Research Organisation agrees to allow Kazia, its Personnel,
and authorized employees of any relevant regulatory body, access to the Project site (or any other location at which Services are being conducted), its Personnel and all records pertaining to the Project, audit records, documents and other data
relating to the Project (other than Identifiable Personal Information) , which records may be redacted of any Confidential Information of other parties to whom Research Organisation owes an obligation of confidentiality (and provided that, in the
event that the receiving party must redact third party Confidential Information, it will provide the disclosing party with a log containing a general, non-identifiable description of the redacted information)
with reasonable advance notice and during normal business hours for the purpose of determining compliance with the terms of this Agreement and compliance with Applicable Laws. 

 

	13.4	 In the event that any regulatory authority carries out, or gives notice of its intention to carry out, an inspection of
the Research Organisation’s facilities, or any other location at which the Project is being conducted or otherwise takes any action in relation to the Project , the Research Organisation shall immediately upon becoming aware of such inspection,
notify Kazia in writing and shall specify in any such notice full details of any action taken or proposed by the relevant regulatory authority. The Research Organisation shall (so far as is consistent with Applicable Law) make any book, record,
documents or information in relation to the Project available to the regulatory authority upon request and shall co-operate with the regulatory authority in connection with any such action, including by providing a duly authorized representative of
the regulatory authority access to the Research Organisation’s facilities and/or any other location in which the Project is being conducted. 

  
 13 

  
  

	14.	 Insurance 

14.1      Each Party agrees to maintain a valid policy or program of insurance or self-insurance at levels and coverages sufficient to
support its obligations assumed herein. Each Party shall provide a written documentation of such coverage upon request by other Party. 
  

 
  

	15.	 Intellectual Property 

  

	15.1	 Each Party acknowledges and agrees that Background Intellectual Property remains the property of the Party contributing
that Background Intellectual Property. 

  

	15.2	 Each Party agrees to take all necessary steps to protect the Background Intellectual Property of the other Party and to
give each other prompt notice of any infringement of the Background Intellectual Property which comes to their attention. Each Party agrees to give each other all assistance reasonably required to protect the Background Intellectual Property. The
Party requiring the assistance shall meet any reasonable costs and expenses incurred by the Party providing the assistance. 

  

 
 Research Organisation grants Kazia a royalty-free nonexclusive
license to all data, discoveries or inventions developed or generated pursuant to this Agreement which relate to any information or materials, including the Test Materials, provided by Kazia under the Agreement and including new data, uses,
processes or compositions directly relating to the information or materials provided by Kazia in connection with or related to the Services or a Project. Furthermore, Research Organisation grants to Kazia an exclusive option to obtain a royalty
bearing, exclusive license under Research Organisation’s right to such data, discoveries or inventions. 
  

 
  

	16.	 Data Use 

  

	16.1	 Terms regarding the data to be provided by Research Organisation to Kazia shall be as negotiated in each study specific
Work Order. 

  
  

 

	17.	 Publications 

  

	17.1	 Kazia recognises that Research Organisation may wish to publish or otherwise publicly disclose the results of the
Project. Research Organisation agrees to 

  

	 	(a)	 submit all such intended publications or presentations to Kazia at least thirty (30) days prior to any intended
submission or other public disclosure for Kazia’s review and comment; and 

  

	 	(b)	 to delete any Confidential Information belonging to Kazia. 

  
 14 

	17.2	 During Kazia’s thirty (30) day review period, upon request from Kazia, Research Organisation agrees to delay
submission for publication by up to ninety (90) days from the date an intended publication is provided to Kazia to allow Kazia to seek legal protection of Intellectual Property. 

 

	17.3	 No Party may use the name or indicia (including logos) of another Party without the prior written consent of that other
Party. 

  
  

 

	18.	 Use of Name and Promotional Activities 

 

	18.1	 Neither Party shall use the name or trademarks of the other Party or the names of current employees, affiliated
physicians or faculty for publicity, advertising or other announcement purpose, except with the prior written consent of the other Party. By entering into this Agreement, the Research Organisation does not directly or indirectly endorse any product
or service of Kazia or any third party that is or will be provided, whether directly or indirectly related to this Agreement. 

  

 
  

	19.	 Liability 

  

	19.1	 Kazia and Research Organisation shall each be liable for its own negligence or wrongful misconduct and the negligence or
wrongful misconduct of its respective officers, directors, employees and agents in connection with the Project. 

  

	19.2	 Neither Party will be liable to the other Party for penalties or liquidated damages or for special, indirect,
consequential, punitive, exemplary or incidental damages of any kind regardless of whether any such losses or damages are characterized as arising from breach of contract, breach of warranty, tort, strict liability or otherwise, even if the other
Party is advised of the possibility of such losses or damages, or if such losses or damages are foreseeable. 

  

	19.3	 The Parties’ liability under this Agreement or any Work Order is limited to the total amount paid for the Services
performed by the Research Organisation in the twelve (12) months preceding the claim under all Work Orders in place under this Agreement. This provision does not apply to Claims relating to a breach of clause 9 or alleging death or personal injury
caused by the negligence or intentional misconduct of a Party. 

  

 
  

	20.	 Termination 

  

	20.1	 Either Party may terminate this Agreement or any Work Order by written notice to the other Party if any of the following
events has occurred in respect of the other Party: 

  

	 	(a)	 as necessary to protect the health, safety, or welfare of a subject participating in a study hereunder or under any
applicable Work Order. 

  

	 	(b)	 a material breach of any of its obligations under this Agreement which is capable of remedy and, the other Party fails to
remedy that breach to the reasonable satisfaction of the first Party within 30 days after receipt of written notice from the notifying Party specifying the breach and requiring it to be remedied; or 

  
 15 

	 	(c)	 a material breach of any of its obligations under this Agreement and the breach is not remediable. 

 

	20.2	 Either Party may terminate this Agreement or any Work Order upon 30 days written notice to the other Party.

  

	20.3	 If notice of termination is given by either Party , the Parties agree to cooperate in respect of the transition of
ongoing Services during the period of notice. 

  

	20.4	 If a Work Order is terminated under clause 20.3, the Research Organisation is entitled to be paid: 

 

	 	(a)	 for all Services performed up to and including the date of termination, including any work in progress toward partially
completed Services or incomplete units and milestones, and 

  

	 	(b)	 any additional Services requested by Kazia in connection with the termination. 

 

	20.5	 Either Party may terminate this Agreement or any Work Order immediately on giving written notice to the other Party if
that Party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against it a petition in bankruptcy, or has a receiver appointed for a substantial part of its assets.

  
  

 

	21.	 Consequences of Expiry or Termination 

 

	21.1	 If this Agreement is terminated or expires for any reason, then, in addition and without prejudice to any other rights or
remedies available to either Party: 

  

	 	(a)	 the Parties are immediately released from the obligations to continue to perform the Agreement except those obligations
that by their nature survive termination; 

  

	 	(b)	 the Research Organisation will return to Kazia all Test Materials and, where the Research Organisation terminates this
Agreement under clause 20.2, will refund to Kazia any amounts paid in advance for Services not provided as at the effective date of termination; and 

  

	 	(c)	 the Research Organisation shall use all reasonable efforts, upon the request of Kazia, to complete reports for all Human
Subjects that have been entered into the Project as of the termination date of this Agreement. 

  

	21.2	 Unless specified in the relevant notice, termination of this Agreement will not affect any Work Orders in place at the
effective date of termination. 

  

	21.3	 Termination of this Agreement shall not affect any rights or obligations which have accrued prior to that termination.

  
  

 

	22.	 Assignment 

  

	22.1	 Neither Party may assign nor otherwise transfer this Agreement or any of its rights or obligations hereunder to any third
party without first obtaining the written consent of the other Party, such consent not to be unreasonably withheld. 

  
 16 

  
  

	23.	 Independent Contractors 

  

	23.1	 For purposes of this Agreement, the relationship of the Parties to this Agreement is that of independent contractors and
not agents of each other or joint venturers or partners. 

  

 
  

	24.	 Notices 

  

	24.1	 All notices must be: 

  

	 	(a)	 addressed to the person nominated and to the address or facsimile set out below or to any other address or facsimile
number that a Party may notify to the other. 

 if to the Research Organisation: 

For Clinical Matters 
 Will be determined in
each Work Order 
 For Administrative Matters 

St. Jude Children’s Research Hospital 
 Attn:
Contracts Coordinator 
 Address: 262 Danny Thomas Place, MS 720 

   Memphis, TN 38105 
 Facsimile: 901-525-9015 
 Email: sandra.fields@st jude.org or patricia.johnson@st jude.org 

For Financial Matters 
 St. Jude
Children’s Research Hospital 
 Attn: Rene Jooste 

Address: 262 Danny Thomas Place, MS 720 

   Memphis, TN 38105 
 Facsimile: 901-525-9015 
 Email:
rene.jooste@stjude.org 
 if to Kazia: 

Attn: Chief Medical Officer 
 Address: Suite 502,
20 George Street, Hornsby, NSW 2077 
 Facsimile: +61-2-9476-0388 

Email: gordon.hirsch@kaziatherapeutics .com 
  

	 	(b)	 signed by an authorized official of the Party; and 

 

	 	(c)	 sent to the recipient by hand, email, prepaid post (airmail if to or from a place outside) or by facsimile.

  

	24.2	 Without limiting any other means by which a Party may be able to prove that a notice has been received by other Party, a
notice will be considered to have been received: 

  

	 	(a)	 if sent by hand, when left at the address of the recipient; 

 

	 	(b)	 if sent by pre-paid post, 3 days (if posted) or 10 days (if posted from one country to another) after the date of
posting; or 

  
 17 

	 	(c)	 if sent by facsimile, on receipt by the sender of an acknowledgment or transmission report generated by the sender’s
machine indicating that the whole facsimile was sent to the recipient’s facsimile number; or 

  

	 	(d)	 if sent by email, when the sender receives an automated message confirming delivery or four hours after the time the
email is sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email has not been delivered, whichever occurs first, but if a notice is served by hand or email, or is received
by the recipient’s facsimile, on a day that is not a Business Day, or after 5:00 pm recipient’s local time on a Business Day, the notice will be considered to have been received by the recipient at 9.00 am on the next Business Day.

  
  

 

	25.	 Dispute Resolution 

  

	25.1	 A Party must not start arbitration or other legal proceedings about a dispute arising out of or in connection with this
Agreement unless it first complies with this clause 25, except: 

  

	 	(a)	 where a Party seeks urgent injunctive relief; or 

 

	 	(b)	 where the dispute relates to compliance with this clause 25. 

 

	25.2	 Any dispute arising out of or in connection with this Agreement, including any dispute regarding the existence, validity
or termination of this Agreement, must be referred by the Parties initially to their respective representatives as referred to in clause 2.5 for resolution. 

  

	25.3	 If the representatives of each Party are unable to resolve the dispute within five Business Days (or such other period
agreed by the parties) after the dispute is referred to them, the dispute must be referred to senior managers of each Party. 

  

	25.4	 If the senior managers of each Party are unable to resolve the dispute within ten Business Days (or such other period
agreed by the parties) after the dispute is referred to them, then either Party may refer the matter to arbitration to be heard by a sole arbitrator: 

  

	 	(a)	 the arbitration will be conducted in accordance with the Arbitration Rules of the International Chamber of Commerce
(ICC Rules); 

  

	 	(b)	 the parties will use reasonable endeavours to agree, within a further five Business Days, on a suitably qualified
professional who is not affiliated or engagedin any capacity with either Party to be engaged as the sole arbitrator; 

  

	 	(c)	 if agreement is not reached for the appointment of the sole arbitrator within the period referred to in clause 25.4(a),
either Party may request that the sole arbitrator be appointed in accordance with the ICC Rules; 

  

	 	(d)	 the seat of the arbitration shall be New York; 

 

	 	(e)	 the language of the arbitration shall be English; and 

 

	 	(f)	 the Parties and the sole arbitrator shall at all times treat all matters relating to the proceedings and the award as
confidential. 

  
 18 

  
  

	26.	 Entire Agreement 

  

	26.1	 This Agreement (and the Schedules attached to it) represents the entire understanding of the Parties with respect to the
subject matter hereof. Any modification, amendment or supplement to this Agreement attached hereto shall be in writing signed by an authorized representative of each Party. 

 
  
  

	27.	 Force Majeure 

  

	27.1	 If a Party’s ability to undertake its obligations under this Agreement is affected, or likely to be affected, by a
Force Majeure Event: 

  

	 	(a)	 that Party must promptly give to the other notice of that fact, including: 

 

	 	(i)	 full particulars of the Force Majeure Event; 

 

	 	(ii)	 an estimate of its likely duration; 

 

	 	(iii)	 the obligations affected by it and the extent of its effect on those obligations; and 

 

	 	(iv)	 the steps taken to rectify it; and 

 

	 	(v)	 the obligations under this Agreement of the Party giving the notice are suspended to the extent to which they are
affected by the Force Majeure Event as long as the Force Majeure Event continues. 

  

	27.2	 A Party claiming a Force Majeure Event must use its best endeavours to remove, overcome or minimise the effects of that
Force Majeure Event as quickly as possible. 

  

	27.3	 If a Force Majeure Event continues for more than thirty days the Party not giving notice of the Force Majeure Event may
immediately terminate this Agreement by written notice to the other. 

  

 
  

	28.	 No Waiver 

  

	28.1	 Either Party’s failure to require the other Party to comply with any provision of this Agreement shall not be deemed
a waiver of such provision or any other provision of this Agreement. 

  

 
  

	29.	 Severability 

  

	29.1	 If any of the provisions of, or a portion of any provision of, this Agreement is held to be unenforceable or invalid by a
court of competent jurisdiction, the validity and enforceability of the other portion of such provision and/or the remaining provisions shall not be affected thereby. 

  
 19 

  
  

	30.	 Survival of Provisions 

  

	30.1	 Notwithstanding expiration of this Agreement or termination for any reason, rights and obligations which are expressly
stated or by their nature are intended to survive expiration or termination of this Agreement remain in full force and effect. 

  

 
  

	31.	 Choice of Law 

This Agreement and all matters arising out of or relating to this Agreement shall be governed by the laws of the State of New York, without regard to choice of law
principles. 
  

	32.	 Biological Samples 

  

	31.1	 Biological Samples shall be collected by the Research Organisation for the Project according to the Proposal, Work Order
and the Informed Consent as approved by the applicable IRB. Biological Samples shall be used by the Research Organisation solely for purposes of the Proposal and only as specified in the Proposal Work Order, Informed Consent, and this Agreement;
except that Research Organisation may collect Retained Samples. Research Organisation shall de-identify and store Retained Samples in an institutional bio-bank for use in compliance with applicable IRB
approval, Informed Consent, and authorization forms. All identifiable Retained Samples must be destroyed at the Work Order completion. 

  

	31.2	 All information about the Retained Samples relating to the Test Materials, including whether or not the Project
participant received the Test Material, shall be removed prior to release of Retained Samples to another investigator for other research. Biological Samples are property of the Research Organisation and shall not be used in any manner or for any
purpose other than that described in the Proposal, Work Order and the terms and conditions of the Informed Consent signed by the Project participants or as otherwise authorized by the IRB. 

  
 20 

							
	Executed as an agreement.	 		 	
				
		 		 		 	
	Signed for and on behalf	 		 		 	
	of Kazia Laboratories Pty Ltd 	 		 		 	
	by its duly authorised representative	 		 		 	
	in the presence of:	 		 		 	
				
	DocuSlgned by:	 		 		 	
				
	/s/ Kate Hill	 		 		 	/s/ Gordon Hirsch
	Signature of witness	 		 		 	Signature of authorised representative
				
	Kate Hill    company secretary	 		 		 	Gordon Hirsch, M D, MBA
	Name of witness (please print)	 		 		 	 Name of authorised representative
 (please print)

				
	Signed for and on behalf	 		 		 	
	of St. Jude Children’s Research	 		 		 	
	Hospital, Inc.	 		 		 	
	by its duly authorised representative	 		 		 	
				
	/s/ Daphne U. Williams	 		 		 	/s/ Terrence Geiger
	Signature of witness	 		 		 	Signature of authorised representative
				
	Daphne U. Williams	 		 		 	Terrence Geiger, MD, PhD
	Name of witness (please print)	 		 		 	Name of authorised representative
				
		 		 		 	Title: SVP & Deputy Director for Academic &
		 		 		 	Biomedical Operations

  
 21 

 Schedule 1 
 Contract Details 

 
  
  

	1.	 Commencement Date 

  

	1.1	 This Agreement shall commence on November 17, 2017 

 

	2.	 Term 

  

	2.1	 Unless terminated earlier in accordance with the terms of this Agreement, the Term shall be for a period of five
(S) years following the Commencement Date. 

  
 22 

 Schedule 2 
 List of Kazia
Affiliates and Subsidiaries 
  
  

  
 23 

 Schedule 3 
 Template Work Order

  
  
  

	1.	 Parties 

The Parties to this Work Order are Kazia Therapeutics Limited (“Kazia” or “Sponsor”) and the Research Organisation (“the
Research Organisation”). 
  

	2.	 Background 

Sponsor and the Research Organisation are [authorised Affiliates of] Parties to a Master Services Agreement dated DD MMM YYYY (MSA), the terms of
which will govern the performance of this Work Order. Upon signature by Sponsor and by the Research Organisation, this Work Order is incorporated in and becomes part of the MSA. 

 

	3.	 Term and Termination 

This Work Order commences on DD MMM YYYY (“Effective Date”) and continues until the Services are completed or until this Work Order is
terminated in accordance with the provisions of Clause 20 of the MSA. 
  

	4.	 Title of the Project 

The title of the “Project” is, “TITLE” with proposal number XXXXX (“Proposal”). The Project Proposal has been
prepared under a separate cover and signed on behalf of the Parties for identification purposes. 
  

	5.	 Performance of Services by the Research Organisation 

The Research Organisation agrees to perform Services with respect to the Project as described in the Proposal and the Attachments to this Work Order.

  

	6.	 Data 

  

	7.	 Payment by Sponsor 

In consideration of the performance of Services under this Work Order, Sponsor will pay the Research Organisation in accordance with the Estimated
Budget and the Schedule of Payments in Attachments C and D. [if applicable] the Research Organisation shall reference Sponsor’s purchase order No. [insert] on invoices for Services under this Work Order. Inquiries regarding payment under this
Work Order shall be sent to the following Sponsor representative: 
 Sponsor Contact Name/Title: 

Sponsor Contact Address: 
 Sponsor Contact e-mail/phone #: 

  
 24 

	8.	 Inconsistencies between this Work Order and the MSA 

If there should be any conflict or inconsistency between the MSA and this Work Order and any of its attachments, it is agreed that a specific provision
of this Work Order will take precedence over and supersede the inconsistent or conflicting term of the MSA. 
  

	9.	 Attachments 

The following attachments to this Work Order form part of the Work Order: 
  

					
	                          	 	Attachment “A”      	 	Scope of Work and Transfer of Obligations
			
		 	Attachment “B”	 	Specifications, Assumptions and Estimated Timelines
			
		 	Attachment “C”	 	Estimated Budget
			
		 	Attachment “D”	 	Schedule of Payments and Terms
			
		 	Attachment “E”	 	Proposal

  

			
	Signed on behalf of	  	Signed on behalf of
		
	“The Research Organisation”	  	Kazia Therapeutics Limited
		
	By:	  	By:
		
	Name:	  	Name:
		
	Title:	  	Title:
		
	Date:	  	Date:

  
 25 

 SJPl3K Work Order 
  

 
  

	1.	 Parties 

The Parties to this Work Order are Kazia Therapeutics Limited (“Kazia”) and St. Jude Children‘s Research Hospital (“the Research
Organisation” or “Sponsor”). 
  

	2.	 Background 

Kazia and the Research Organisation are Parties to a Master Services Agreement dated 17 November 2017 (MSA), the terms of which will govern the
performance of this Work Order. Upon signature by Kazia and by the Research Organisation, this Work Order is incorporated in and becomes part of the MSA. 
  

	3.	 Term and Termination 

This Work Order commences on 30 June 2018 (“Effective Date”) and continues until the Services are completed or until this Work Order is
terminated in accordance with the provisions of Clause 20 of the MSA. 
  

	4.	 Title of the Project 

The title of the “Project” is, “PHASE 1 STUDY OF GDC-0084, A BRAIN-PENETRANT Pl3 KINASE/mTOR INHIBITOR, IN PEDIATRIC PATIENTS WITH NEWLY
DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA OR OTHER DIFFUSE MIDLINE GLIOMAS AFTER RADIATION THERAPY” (“Protocol”). The Project Protocol has been prepared under a separate cover and signed on behalf of the Parties for identification
purposes. 
  

	5.	 Investigator 

Christopher Tinkle, MD, PhD, an employee of the Research Organisation acting within the scope of his/her employment shall serve as the principal
investigator (“Investigator”) for the Project and has the necessary qualifications, training, knowledge and experience to conduct such a clinical trial. 

Amar Gajjar, MD, an employee of the Research Organisation acting within the scope of his/her employment shall serve as the co-principal investigator (“Co-lnvestigator”) for the Project and has the necessary qualifications, training, knowledge and experience to conduct such a clinical trial. 

 

	6.	 Performance of Services by the Research Organisation 

The Research Organisation agrees to perform Services with respect to the Investigator initiated study Project as described in the Protocol and the
Attachments to this Work Order. 

  
 1 

	7.	 Data 

In recognition of the importance of disseminating information relating to any novel or important observations or results related to the Study Drug and
arising from the Protocol (“Study Data” ), the parties hereby agree to the following: 
  

	 	A.	 The Study Data and all copyrights therein shall be the property of the Research Organisation, subject to the right of
Kazia as specified below. 

	 	B.	 The Research Organisation shall ensure that the Study Data are kept in orderly, safe, and secure storage in accordance
with regulatory requirements for document retention following the local archiving regulations for such data. 

	 	C.	 The Research Organisation shall grant Kazia access to all Study Data generated for study primary objectives, secondary
objectives, exploratory pharmacodynamic and pharmacogenetic objectives, and exploratory biology objectives as outlined in the Protocol in the course of the Study at no additional cost. Kazia shall have the right to make copies of these Study Data.
Notwithstanding any other provision of the Agreement, Kazia and its Affiliates and their licenses or sublicenses shall have the right in perpetuity to use these Study Data for all purposes, including, but not limited to regulatory purposes (e.g.
pediatric study plan (PSP), or paediatric investigation plan (PIP)), patent purposes, public information disclosure responsibilities, and publication reference purposes at no additional costs. 

	 	D.	 The Research Organisation shall notify Kazia of any suspected unexpected serious adverse reactions (“SUSARs”)
during the course of the Study within 24 hours of notification of their occurrence, so that Kazia may fulfil its regulatory reporting requirements. The Research Organisation shall reasonably support any necessary follow-up of SUSARs. In addition,
the Research Organisation shall provide quarterly safety listings to Kazia for in clusion in its mandatory regulatory filings. 

	 	E.	 The Research Organisation shall ensure that the patient informed consent identifies all anticipated purposes for the use
of Study Data and shall ensure patient informed consent permits the sharing of Study Data generated for study primary objectives, secondary objectives, exploratory pharmacodynamic and pharmacogenetic objectives, and exploratory biology objectives as
outlined in the Proposal with Kazia, its affiliates and any successors of either party, including those located outside the United States. In obtaining and documenting that patient informed consent, the Research Organization shall comply with the
applicable regulatory requirement(s) and shall adhere to Good Clinical Practices as set forth in Title 21 of the U.S. Code of Federal Regulations and to the ethical principles as laid out in the Declaration of Helsinki. 

	 	F.	 The Parties agree that Study Drug related research safety data generated during the course of the Study may be used
fully by Kazia for any legitim ate businesspurpose without any additional payments being made to Institution. 

  

	8.	 Disclosure 

The terms of this Work Order shall remain confidential between the Parties. Notwithst anding this, it is acknowledged that Kazia , as a publicly-listed
company, may be obliged from time to time to make disclosures regarding the existence and progress of this Study. 

  
 2 

	9.	 Payment by Kazia 

In consideration of the performance of Services under this Work Order, Kazia will pay the Research Organisation in accordance with the Estimated Budget
and the Schedule of Payments in Attachments C and D. [if applicable] the Research Organisation shall reference Kazia’s purchase order No. on invoices for Services under this Work Order. Inquiries regarding payment under this Work Order shall be
sent to the following Kazia representative: 
 Kazia Contact Name/Title: Gabrielle Heaton, Director, Finance & Administration 

Kazia Contact Address: Three International Towers, Sydney NSW 2000 

Kazia Contact e-mail/ phone #: gabrielle.heaton@kaziatherapeutics.com / +61 (O) 418 532 393 
  

	10.	 Inconsistencies between this Work Order and the MSA 

If there should be any conflict or inconsistency between the MSA and this Work Order and any of its attachments, it is agreed that a specific provision
of this Work Order will take precedence over and supersede the inconsistent or conflicting term of the MSA. 
  

	11.	 Attachments 

The following attachments to this Work Order form part of the Work Order: 
  

					
		 	Attachment “A”	 	Scope of Work and Transfer of Obligations
			
		 	Attachment “B”	 	Specifications, Assumptions and Estimated Timelines
			
		 	Attachment “C”	 	Budget
			
		 	Attachment “D”	 	Schedule of Payments and Terms
			
		 	Attachment “E”	 	Protocol
			
		 	Attachment “F”	 	GMP Responsibilities
			
		 	Attachment “G”	 	Shipment Request Form

 (REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 3 

									
	Signed on behalf of	 		 	Signed on behalf of
			
	“The Research Organisation”	 		 	Kazia Therapeutics Limited
					
	By:	 	/s/ Terrence
Geiger                                        
      	 		 	By:	 	/s/ James
Garner                                        
      
	Name:	 	Terrence Geiger, MD, PhD                               	 		 	Name:	 	James
Garner                                        
           
	Title:	 	SVP & Deputy Director for Academic	 		 	Title:	 	Chief Executive
Officer                                     
		 	and Biomedical Operations	 		 	Date:	 	October 2,
2018                                         
       
					
	Date:	 	September 28,
2018                                         
     	 		 		 	

  

									
	Read and Acknowledge	 		 	Read and Acknowledge
					
	By:	 	/s/ Christopher
Tinkle                                        
    	 		 	By:	 	/s/ Amar
Gajjar                                        
         
	Name:	 	Christopher Tinkle, MD,
PhD                                 	 		 	Name:	 	Amar Gajjar,
MD                                         
     
	Title:	 	Investigator                                    
                       	 		 	Title:	 	Co-Investigator                                   
              
	Date:	 	September 13,
2018                                         
   	 		 	Date:	 	September 12,
2018                                         

  
 4 

 ATTACHMENT A 

SCOPE OF WORK AND TRANSFER OF OBLIGATIONS 
 The study to be
performed under this agreement shall be performed in accordance with the terms of the final protoco,l including as it may be amended in accordance with the terms of this agreement for the study titled SJPl3K: Phase 1 Study of GDC-0084, A Brain
Penetrant Pl3Kinas e/ mTOR Inhibitor, in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas or Other Diffuse Mid line Gliomas after Radiation Therapy (the Proposal), which is attached as Attachment E and incorporated into this
work order as reference. Where St. Jude Children‘s Research Hospital (the Research Organisation) is the study sponsor of this Investigator initiated study and Kazia Therapeutics Limited (Kazia) is providing financial support per Attachment C,
study drug, and shipment of study drug. 
 The Research Organisation certifies that, to the best of its knowledge, its facilities and population are adequate to
perform the Proposal , SJPl3K. The Research Organisation and the Principal Investigator agree that all aspects of the Proposal will be conducted in conformity with all applicable federal, state, local laws and regulations, and the principles of good
clinical practice as laid down by ICH topic E6, Note for Guidance on Good Clinical Practice CPMP/ICH/135/95 (hereinafter referred to as GCP). The Research Organisation and the Principal Investigator further agree not to conduct any research
activities with the Study Drug which are contract to the provision of the protocol our outside the scope of the Proposal. The Research Organisation will serve as the legal sponsor of the protocol and will fulfill the requisite sponsor duties and
obligations in conducting the Proposal. 
 The clinical trial’s primary objectives are to: estimate the maximum tolerated dose (MTD) and/or recommended phase 2
dose (RP2D) of GDC-0084 in pediatric patients with newly diagnosed midline glioma, including diffuse intrinsic pontine glioma (DIPG); define and describe the to xicities associated with administering GDC-0084
after radiation therapy (RT) in a pediatric population; characterize the pharmacokinetics of GDC-0084 in a pediatric population. 

The clinical trial‘s secondary objectives are to: estimate the rate and duration of radiographic response in patients with newly diagnosed DIPG or other diffuse
midline glioma treated with RT followed by GDC- 0084; estimate the progression-free survival (PFS) and overall survival (OS) distributions for patients with newly diagnosed DIPG or other diffuse midline glioma
treated with RT followed by GDC-0084. 
 The clinical trials exploratory pharmacodynamic and pharmacogenetic objectives are
to: explore the biologic activity of GDC-0084 by evaluating protein phosphorylation of AKT, S6, and 4EBP1 in peripheral blood mononuclear cells (PBMCs) before, during, and after treatment with GDC-0084; evaluate molecular markers of the Pl3K signaling pathway in archival tumor tissue when available; explore the association between specific polymorphisms (CYP3A/ 4/ 5, PgP, etc.) and the pharmacokinetics of
GDC-0084. 
 The clinical trials exploratory biology objectives are to: identify characteristic alterations in diffuse
midline glioma in cell-free DNA (cfDNA) in biologic samples (blood and, when available, CSF) as a novel, 

  
 5 

 non-invasive method of detecting and tracking changes in the status of
diffuse midline glioma with therapy and to assess the correlation of cfDNA and mutations in archival tumor samples, when available; perform immune-cell profiling in serial blood samples and, when available, in CSF and archival tumor samples and to
explore associations of these findings with ORR, PFS, and OS estimates; perform single-cell RNA sequencing on archival tumor samples, when available, and to characterize tumor subpopulations . 

The clinical trials exploratory imaging objectives are to: assess intralesional changes induced by RT alone by using advanced MRI techniques (perfusion, diffusion, and
spectroscopy), to investigate whether those changes are correlated with clinical response and/or survival outcomes, and to determine whether such metrics differentiate patients with pseudoprogression from those with true progressive disease after
completion of RT; evaluate changes in tumor (18F]fluorod eoxyglucose(FDG) uptake as assessed by positron emission tomography (PET) during the first cycle of
GDC-0084 administration; evaluate changes in tumor [11C]m ethionine (MET) uptake as assessed by PET imaging during the first three cycles of GDC-0084
administration and to determine whether MET-PET metrics differentiate patients with pseudoprogression from those with true progressive disease. 

The clinical trials exploratory outcome objective is to explore the feasibility and interobserver variability of administering the modified Neurologic Assessment in
Neuro-Oncology (NANO) scale test to pediatric patients with DIPG or other diffuse midline glioma. 
 To achieve these objectives, The Research Organisation and Kazia
agree to perform the following study-related activities 
 Scope of Work by Party: 
  

	•	 	 St. Jude Children’s Research Hospital (the Research Organization): 

 

	 	•	 	 IND Holder and Study Sponsor 

  

	 	•	 	 Regulatory Preparation, Submissions, and Reporting per Guidelines. Reporting to Kazia per SJPl3K Protocol.

  

	 	•	 	 Clinical Trial Monitoring 

  

	 	•	 	 Clinical Trial Advertising 

  

	 	•	 	 Study Drug Labeling and Storage (Limited Supply), Distribution to Patients, and Destruction (per Kazia Requirements)

  

	 	•	 	 Patient Recruitment, Consenting, and Enrollment 

 

	 	•	 	 Dose Level and Strata Assignment 

 

	 	•	 	 Patient Clinical Assessments 

  

	 	•	 	 All Research Exams 

  

	 	•	 	 Data Collection and Storage 

  

	 	•	 	 Sample Collection, Storage, Processing, and Analysis per Research Objectives 

 

	 	•	 	 Pharmacokinetic Sample Analysis and Modeling 

 

	 	•	 	 Biostatistical Analysis 

  

	 	•	 	 Provide Trial Funding per Attachment C 

  
 6 

	 	•	 	 Study Report Development 

  

	 	•	 	 Publication/Poster/Presentation Development 

 

	•	 	 Kazia Therapeutics Limited (Kazia): 

 

	 	•	 	 Provide Cross Reference Letter to Kazia IND for St. Jude IND Submission 

 

	 	•	 	 Notify St. Jude of GDC0084 Safety-Related Events in Adult Trials 

 

	 	•	 	 Provide latest and updated 1B 

  

	 	•	 	 Provide Study Drug, Shipment to St Jude, Instructions for Study Drug Destruction 

 

	 	•	 	 Provide Partial Trial Funding per Attachment C 

 

	 	•	 	 Review Protocol Amendments in a Timely Manner 

 

	 	•	 	 Review Publication/Poster/Presentations in a Timely Manner 

  
 7 

 ATTACHMENT B 

SPECIFICATIONS, ASSUMPTIONS AND ESTIMATED TIMELINES 
 Study
Name: Phase 1 Study of GDC-0084, A Brain Penetrant Pl3Kinase / mTOR Inhibitor, in Pediatric Patient s with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas or Other Diffuse Mid line Gliomas after Radiation Therapy (SJPl3K) 

Study Site: St. Jude Children’s Research Hospital 
 Targeted Number
of Study Subjects: Up to 41 Subjects 
 As the Rolling-6 design allows for up to six patients at each dose level, and
given the relatively long period between enrollment and the end of the DLT observation period, we anticipate that we may enroll six patients per dose level for Stratum Al. Given that up to four dose levels will be studied and that the cohort at the
MTD will be expanded to 12 patients, we anticipate a maximum enrollment of 30 evaluable patients for the dose-finding component. Taking into account the accrual of six additional patients for Stratum A2 after the completion of Stratum Al, we may
enroll a total of 36 eligible and evaluable patients. It is typical to encounter eligible patients who enroll on a phase 1 trial but become unevaluable for toxicity assessmentas a result of their inability to complete the DLT observation period.
Thus, we may enroll three to five additional patients to compensate for the loss to the study of patients due to in evaluability, for a total estimated sample size of 41 patients. 

Estimated Recruitment Period: August 2018 - August 2021 
 We expect to
enroll one or two patients per month. Thus, the MTD estimation should be completed within 2 years after study initiation, and we expect that up to 1 additional year may be needed to complete the expansion cohorts. 

Principal Investigator Name: Chri stopher Tinkle, MD 
 Co-Principal Investigator Name : Amar Gajjar, MD 
 Address: St. Jude Children’s Research Hospital 

                262 Danny Thomas Place, MS 210 

                Memphis, TN 38105 

Responsible Institutional Review Board (IRB): St. Jude Children‘s Research Hospital In stitutional Review Board 

  
 8 

 Attachment C 

SJPl3K Study Budget 
 Kazia 

 

									
	Activity	  	Unit Cost	  	 Max Possible

Units (n)
	  	Activity Total (Max+ includes Overhead)	  	CPTCodes
	 All Subject to Overhead
	  	 %
overhead for all activities (not included with unit cost below)
  
	  	 	  	 	  	 
	 REQUIRED
EXAMS

	 Contraception Counseling
	  	 	  	 	  	 	  	99211
	 Venipuncture
	  	 	  	 	  	 	  	36415
	 Pregnancy Test (urine or serum)
	  	 	  	 	  	 	  	81025 and 84702
	 Pharmacy Oral Dose - per

course dispense per drug
	  	 	  	 	  	 	  	No CPT Code Standard Pharmacy Fee
	 Pharmacokinetics Serum
	  	 	  	 	  	 	  	 36415, 36591, 36592,
99000,
 99001, 99195

	 Matched Pharmacokinetics CSF

and Serum
	  	 	  	 	  	 	  	 36415, 36591, 36592,
99000,
 99001, 99195

	 OPTIONAL RESEARCH
EXAMS

	 Pharmacodynamic Tissue

Sample
	  	 	  	 	  	 	  	 36415, 36S91, 36592,
99000,
 99001, 99195

	 Pharmacodynamic Serum PBMC
	  	 	  	 	  	 	  	 36415, 36591, 36592,
99000,
 99001, 99195

	 Per Patient Costs
Summary..

  
 9 

  

									
	Per Patient Cost (assumes patients receive RT + 26 courses of thera py)	  	 	  	 Patients Max Kazia:

Responsible for first patients SJCRH:
 Responsible for

remaining patients
	  	Kazia Per Pt Max:	  	Kazia Total:
	 Administrative and
Regulatory Fees
  

	 SAE Reporting
	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 Kazia Admin + Reg Total:

 
	  	 
	  

Pharmacokinetic Research Fees

	 Pharm acokinetics Orders

Startup Fee (one time)
	  	 	  	 	  	 	  	 
	 Pharm acokinet ic Analysis CRA
	  	 	  	 	  	 	  	 
	 Pharmacokinetic Senior

Research Technician
	  	 	  	 	  	 	  	 
	 Pharmacokinetic Biomedical

Modeler
	  	 	  	 	  	 	  	 
	 Pharmacokinetic Analysis

Startup Fee and Annual

Supplies
	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	Kazia Total:	  	 

  
 10 

									
	Activity	  	Unit Cost	 	 Max Possible

Units (n)
	  	Activity Total (Max+ includes Overhead)	  	CPTCodes
	 All Subject to Overhead
	  	 % overhead for all activities (not
included with unit cost below)
  
	 	 	  	 	  	 
	 OPTIONAL RESEARCH
EXAMS

	 Pharmacodynamic ct DNA
	  	 	 	 	  	 	  	36415, 36591, 36592, 99000, 99001, 99195
	 Pharmacodynamic PB Lymphocytes
	  	 	 	 	  	 	  	36415, 36591, 36592, 99000, 99001,99195
	 Exploratory MRI
	  	 	 	 	  	 	  	76390, 76377
	 Exploratory FOG-PET
	  	 	 	 	  	 	  	78813-78816;
	 Exploratory MET-PET
	  	 	 	 	  	 	  	78813-78816
	 NANO Assessment
	  	 	 	 	  	 	  	99211
	
PERSONNEL

	 Principal Investigator
	  	 	 	 	  	 	  	 
	 Research Nurse/Study coordinator
	  	 	 	 	  	 	  	 
	 Data Manager
	  	 	 	 	  	 	  	 
	 
	
Per Patient Costs Summary••

  

  
 11 

									
	Per Patient Cost (assumes 28 patients receive RT + 26 courses of therapy)	  	 	  	
Patients Max
	  	St . Jude Per Pt Max:	  	 St. Jude Total :

 
 St. Jude Total (with safety assessments for up to patients):

 

	 Administrative and Regulatory Fees

 

	Administrative Startup Fees (one time)	  	 	  	 	  	 	  	 
	lnvestigational Pharmacy Startup (one time)	  	 	  	 	  	 	  	 
	 lnvestigational Pharmacy

Storage Fee (annual)
	  	 	  	 	  	 	  	 
	Regulatory Prep (one time)	  	 	  	 	  	 	  	 
	 IRB Review (initial review first

submission)
	  	 	  	 	  	 	  	 
	 Record Storage/Archiving IRB

records (onetime fee)
	  	 	  	 	  	 	  	 
	Budget/MCA Fee	  	 	  	 	  	 	  	 
	Annual IRB Review (per occurrence)	  	 	  	 	  	 	  	 
	Amendment (per occurrence)	  	 	  	 	  	 	  	 
	Reconsent	  	 	  	 	  	 	  	 
	IND (includes miscellaneous cost for institution to hold the IND)	  	 	  	 	  	 	  	 
	Project Management	  	 	  	 	  	 	  	 
	Translation Fees	  	 	  	 	  	 	  	 
	Protocol Monitoring	  	 	  	 	  	 	  	 
	EDC and eCRF development and testing	  	 	  	 	  	 	  	 

  

  
 12 

  

			
		  	
	 	  	 
	 	  	St. Jude Admin + Reg Total:

  
  

 

							
	
Budget Summary

	 Activity

 
	  	 St. Jude Children’s Research
Hospital
  
	  	 Kazia

 
	  	 Total

 

	 Patient Assessments (Max Possible)

 
	  	 	  	 	  	 
	 Administrativeand Regulatory Fees

 
	  	 	  	 	  	 
	 Pharmacoklnetic Research

 
	  	 	  	 	  	 
	 Total

 
	  	 	  	 	  	 

  
 The funding for this study may be offset by
independent grant support. This may be grant support of research organization alone of in collaboration with Kazla. In the latter case, the distribution of funds will be agreed at the time of grant award. 

  
 13 

 Attachment D 

Schedule of Payments and Terms 
  

							
	Amount w/
overhead	  	Expected
Payment Date	  	Condition of
Payment	  	Total w/overhead
	 	  	Invoiced	  	Patient costs for first patients (invoice monthly as patients are accrued)	  	 
	 	  	Invoiced	  	SAE Reporting (total 15)	  	 
	 	  	Invoiced	  	 Pharmacokinetic

Start Up Fee
	  	 
	 	  	Invoiced	  	 Pharmacokinetic

CRA Analysis (3 years total)
	  	 
	 	  	Invoiced	  	Pharmacokinetic Senior Research Tech (3 years total)	  	 
	 	  	Invoiced	  	Pharmacokinetic Biomedical Modeler (3 years total)	  	 
	 	  	Invoiced	  	Pharmacokinetic Analysis Start Up Fee and annual supplies (3 years total)	  	 
	 Kazia Total Budget

 
	  	 	  	 	  	 

  
 14 

 Attachment E 

PROTOCOL 
 (Attached by reference) 

  
 15 

 Attachment F 

GMP Responsibilities 
  

							
	 
	
GMP Responsibilities for Phase l Clinical Study Drug

GDC-0084 Capsules

 

	
Background & Scope:

(i)  St. Jude Children’s Research Hospital plans to Sponsor a Phase 1 pediatric clinical study under
clinical protocol SJPI3K with GMP responsibilities as indicated below.
 (ii)   Kazia will
supply to St Jude GMP manufactured and primary packed Study Drug (lnvestigational Medicinal Product - IMP) for Phase 1 clinical trial use in the US under St Jude clinical protocol SJPI3K. Kazia GMP responsibilities as indicated
below.

	#	 	Responsibility	  	Kazia    	  	St Jude    
	
I
	 	IMP: Supply of GMP manufactured and primary packed (unlabelled) Study Drug GDC-0084 capsules) in the agreed strengths (active only, no placebo), with
suooorting GMP documentation (e.g. manufacturers CoAs)	  	X    	  	 
	
r2
	 	IMP: Each bottle of Study Drug supplied will be identified (either labelled or ink-jet orinted) with unique lot
number to prevent risk of mix-up	  	X    	  	 
	
3
	 	 Retest Date & Storage
Conditions: Provision of retest date(s) and storage conditions for the Study Drug supplied
	  	X    	  	 
	 	 	 IMP Ordering: Requests for Study Drug shipment will be
provided to Kazia in !writing
	  	 	  	X  
	
5
	 	 !Shipping: Will ship Study Drug to St Jude
accompanied by relevant paperwork (e.g. !packing list)
	  	X    	  	 
	
ki
	 	 Receipt & Labelling:
Receive, store and label Study Drug for clinical trial use
	  	 	  	X  
	
7
	 	 Release of IMP: responsibility for release of
labelled Study Drug for Phase I clinical !trial use in US
	  	 	  	X  
	
8
	 	Product Defects I Product Complaints: will promptly notify the other party if a Product Quality Defect is observed or reported (e.g. damaged
Study Drug capsules or !Primary packaging)	  	X    	  	X  
	
19
	 	!Product Recall: Kazia are overall responsible for any product recall decision. Kazia i will notify St Jude in the event of a Product Recall and both
parties will work together las may be required to coordinate both the Recall activities and notifications to the elevnt regulatory authorities as may be applicable [Note: Product Recall may also be referred to as “stock recovery” in
certain territories (e.g. US) as the Sponsor exerts direct control over the drugl.	  	X    	  	X  
	
10
	 	Returns & Destruction: Responsibility for any returns and destruction rests with rNote: the process for destruction to be agreed
with Kazial	  	 	  	X  

  
 16 

 Attachment G 

Shipment Request Form 

  
 17 

 AMENDMENT No. 1 to the 

Work Order 
 This Amendment No. 1 (“Amendment”) is entered into as of May 15, 2019 (the “Effective Date”) by and between St. Jude Children’s Research Hospital, Inc., located at 262 Danny Thomas Place, Memphis,
Tennessee 38105 (“St. Jude” or “Sponsor” ) and Kazia Therapeutics Limited (“Kazia”, located at Suite 502, Level 5, 20 George Street, Horns by, NSW 2077, for the Study entitled “PHASE 1 STUDY OF GDC-0084, A BRAIN-PENETRANT Pl3 KINASE/mTOR INHIBITOR, IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA OR OTHER DIFFUSE MIDLINE GLIOMAS AFTER RADIATION THERAPY”
(“Protocol”). 
  

	 	RECITALS	 

	 	A.	 The Parties entered into a Master Agreement effective 17 November 2017. 

	 	B.	 The Parties entered into a Work Order under that Master Agreement effective 30 June 2018.

	 	C.	 The Parties wish to amend the terms of the Work Order as set forth below.

 1. Change in Attachment D - Schedule of Payments and Terms. Attachment D is hereby
deleted and replaced with the following 
 Attachment D 

Schedule of Payment and Terms 
  

							
	 Amountw/

overhead
	  	 Expected
 Payment
Date
	  	Condition of Payment	  	Total w/ overhead
	 	  	Invoiced	  	Patient costs for 28 patients (invoice monthly as patients are accrued)	  	 
	 	  	Invoiced	  	SAE Reporting (total 15)	  	 
	 	  	Invoiced	  	Pharmacokinetic Start Up Fee	  	 
	 	  	 Invoiced
 every 6

months
 starting 1st

July 2018
 until last payment on 1st January 2021.
	  	Pharmacokinetic CRA Analysis (3 years total)	  	 
	 	  	 Invoiced

every 6
 months
	  	 Pharmacokinetic Senior

Research Tech (3 years total)
	  	 

 IN WITNESS WHEREOF, the parties agree to the above terms, have caused this Agreement to be executed and delivered by
their authorized representatives, and acknowledge receipt of a copy of this Agreement. 

ST. JUDE CHILDREN’S RESEARCH HOSPITAL, INC. 
  

			
	By:	 	/s/ Terrence Geiger
	Name:	 	Terrence Geiger, M.D., Ph.D.
	Title:	 	SVP & Deputy Director for Academic & Biomedical Operations
	Date:	 	June 18, 2019

 KAZIA THERAPEUTICS LIMITED 

			
	By:	 	/s/ James Garner
	Name:	 	James Garner
	Title:	 	Chief Executive Officer
	Date:	 	June 7, 2019

 Read and Acknowledged By: 

			
	/s/ Christopher Tinkle
	Christopher Tinkle, MD, PhD, Investigator
	Date:	 	June 12, 2019

 Read and Acknowledged By: 

			
	/s/ Amar Gajjar
	Amar Gajjar, MD, Co-Investigator
	Date:	 	June 12, 2019

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]